{ "entity_id": "B-001935", "folder": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "name": "National Health and Medical Research Council - Commissioner of Complaints", "type": "Statutory Body", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "https://www.nhmrc.gov.au/about-us/leadership-and-governance/council", "data_status": "rich", "completeness": { "has_strategy_brief": true, "has_strategy_structured": true, "has_vision": false, "has_kpi_targets": true, "has_kpi_results": true, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_ideas": true, "has_artifacts": true, "n_ideas": 12, "n_legislation": 0, "n_artifacts": 18, "n_kpi_targets": 4, "n_kpi_results": 4, "n_outcomes": 3, "verified_own_data": true }, "strategy_profile": { "status": "published", "confidence": "high", "summary": "NHMRC’s purposes support our mission of building a healthy Australia and collectively capture NHMRC’s legislated functions. [CP p.10]", "official_site_url": "https://www.nhmrc.gov.au/about-us/leadership-and-governance/council", "source_documents": [ { "type": "annual_report", "title": "Annual Report 2024–25", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf", "period": "2024-25", "confidence": "high" }, { "type": "annual_report", "title": "Annual Report 2023–24", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf", "period": "2023-24", "confidence": "high" }, { "type": "annual_report", "title": "2016–17", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf", "period": "2016-17", "confidence": "high" }, { "type": "annual_report", "title": "2015–16", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf", "period": "2015-16", "confidence": "high" }, { "type": "annual_report", "title": "2014–15", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf", "period": "2014-15", "confidence": "high" }, { "type": "corporate_plan", "title": "NHMRC Corporate Plan 2025–26", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "period": "2025-26", "confidence": "high" }, { "type": "corporate_plan", "title": "NHMRC Corporate Plan 2024–25", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf", "period": "2024-25", "confidence": "high" }, { "type": "corporate_plan", "title": "2018–19", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/77446457-0aed-405b-b234-73321c169df2/upload_pdf/corporate-plan-2018-2019.pdf;fileType=application%2Fpdf", "period": "2018-19", "confidence": "high" }, { "type": "corporate_plan", "title": "2017–18", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/4ba2e828-a6a9-4c84-beab-a45c39967b6e/upload_pdf/17293_nhmrc_corporate_plan_2017-18-web.pdf;fileType=application%2Fpdf", "period": "2017-18", "confidence": "high" }, { "type": "corporate_plan", "title": "2016–17", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf", "period": "2016-17", "confidence": "high" }, { "type": "strategie", "title": "NHMRC Gender Equity Strategy", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/NHMRC_Gender_Equity_Strategy_FA.pdf", "period": null, "confidence": "medium" }, { "type": "strategie", "title": "National Framework for Consumer Involvement in Cancer Control | Cancer Australia", "url": "https://www.canceraustralia.gov.au/sites/default/files/migrated-files/publications/national_consumer_framework_web_504af020f2184.pdf", "period": null, "confidence": "medium" } ], "purpose": { "text": "NHMRC’s purposes support our mission of building a healthy Australia and collectively capture NHMRC’s legislated functions. [CP p.10]", "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": 10, "source_deep_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=10" }, "vision": null, "strategic_priorities": [ { "title": "Aboriginal and Torres Strait Islander health", "description": "Aboriginal and Torres Strait Islander health", "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": 18, "source_deep_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18" }, { "title": "Artificial intelligence in health", "description": "Artificial intelligence in health", "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": 18, "source_deep_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18" }, { "title": "Emerging health threats and emergencies", "description": "Emerging health threats and emergencies", "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": 18, "source_deep_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18" }, { "title": "Multiple long-term conditions", "description": "Multiple long-term conditions", "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": 18, "source_deep_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18" } ], "values": [ { "name": "Investment", "description": "", "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": null }, { "name": "Translation", "description": "", "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": null }, { "name": "Integrity", "description": "", "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": null } ], "outcomes": [ { "name": "Outcome 1: Improved health and medical knowledge", "description": "Create knowledge and build research capability through investment in the highest-quality health and medical research, and the best researchers. [AR p.15]", "activities": [ "fund health and medical research and training", "issue guidelines on and advise the community on matters related to health and medical research", "advise the community on ethical issues relating to health" ], "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": 15, "source_deep_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15" }, { "name": "Outcome 2: Translation of health and medical research", "description": "Drive the translation of health and medical research into public policy, health systems and clinical practice and support the commercialisation of research discoveries. [AR p.15]", "activities": [ "fund health and medical research and training", "issue guidelines on and advise the community on matters related to health and medical research", "advise the community on ethical issues relating to health" ], "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": 15, "source_deep_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15" }, { "name": "Outcome 3: Integrity of research", "description": "Maintain a strong integrity framework underpinning rigorous and ethical research, and promoting community trust. [AR p.15]", "activities": [ "fund health and medical research and training", "issue guidelines on and advise the community on matters related to health and medical research", "advise the community on ethical issues relating to health" ], "source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "source_page": 15, "source_deep_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15" } ], "performance_measures": [ { "code": "CCE01", "measure": "Grants are awarded, based on expert peer review, distribution of the value of new grants across the full spectrum of health and medical research, and include national, state and territory and community priorities", "target": "Target/s Methodology Measure type Reporting years", "latest_result": "8.9% of new grants awarded (by value) to research on health in Aboriginal and Torres Strait Islander people", "status": "Achieved", "target_source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "target_source_page": 47, "result_source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf", "result_source_page": 19 }, { "code": "CCE02", "measure": "More than 5% of NHMRC’s annual budget is awarded to research that aims to improve health outcomes for Aboriginal and Torres Strait Islander people", "target": "Quantitative assessment of the number of grants, amount of funding awarded and funded rates by gender, and whether measures have been applied to reduce gender disparities", "latest_result": "4.4% of new grants were led by chief investigators of Aboriginal and/or Torres Strait Islander descent", "status": "Achieved", "target_source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "target_source_page": 47, "result_source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf", "result_source_page": 19 }, { "code": "CCE03", "measure": "Research is conducted responsibly, ethically and with integrity in Australia", "target": "Compliance with regulatory requirements under the Research Involving Human Embryos Act 2002", "latest_result": "Target met", "status": "Achieved", "target_source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "target_source_page": 49, "result_source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf", "result_source_page": 19 }, { "code": "CCE04", "measure": "Research involving human embryos is conducted ethically and legally in accordance with appropriate licence conditions", "target": "Qualitative assessment from inspections and six-monthly reports", "latest_result": "Target met", "status": "Achieved", "target_source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "target_source_page": 49, "result_source_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf", "result_source_page": 19 } ], "document_alignment_terms": { "must_support": [ "NHMRC’s purposes support our mission of building a healthy Australia and collectively capture NHMRC’s legislated functions. [CP p.10]", "Aboriginal and Torres Strait Islander health", "Artificial intelligence in health", "Emerging health threats and emergencies", "Multiple long-term conditions" ], "watch_terms": [ "Grants are awarded, based on expert peer review, distribution of the value of new grants across the full spectrum of health and medical research, and include national, state and territory and community priorities", "More than 5% of NHMRC’s annual budget is awarded to research that aims to improve health outcomes for Aboriginal and Torres Strait Islander people", "Research is conducted responsibly, ethically and with integrity in Australia", "Research involving human embryos is conducted ethically and legally in accordance with appropriate licence conditions" ], "avoid_claiming_without_evidence": [] }, "review_note": "" }, "strategy_brief_md": "# National Health and Medical Research Council - Commissioner of Complaints — Strategy Brief\n\n**Reporting period**: 2024-25\n**Corporate plan in force**: 2025-26\n**Annual Report**: [2024-25](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)\n**Corporate Plan**: [2025-26](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)\n\n## Our purpose / purposes\n\n> NHMRC’s purposes support our mission of building a healthy Australia and collectively capture NHMRC’s legislated functions. [CP p.10](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=10) [[CP p.10](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=10)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=10)]\n\n## How we deliver\n\n> NHMRC’s strategy for health and medical research helps to focus our activity to ensure we achieve our mission of building a healthy Australia and contributes to the broader research and innovation system in Australia. [CP p.13](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=13) [[CP p.13](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=13)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=13)]\n\n## Government priorities for this department\n\n- Aboriginal and Torres Strait Islander health [[CP p.18](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18)]\n- Artificial intelligence in health [[CP p.18](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18)]\n- Emerging health threats and emergencies [[CP p.18](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18)]\n- Multiple long-term conditions [[CP p.18](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=18)]\n\n## Outcomes\n\n### Outcome 1: Improved health and medical knowledge\nCreate knowledge and build research capability through investment in the highest-quality health and medical research, and the best researchers. [AR p.15](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=15) [[CP p.15](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15)]\n\n**Key activities:**\n- fund health and medical research and training\n- issue guidelines on and advise the community on matters related to health and medical research\n- advise the community on ethical issues relating to health\n\n### Outcome 2: Translation of health and medical research\nDrive the translation of health and medical research into public policy, health systems and clinical practice and support the commercialisation of research discoveries. [AR p.15](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=15) [[CP p.15](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15)]\n\n**Key activities:**\n- fund health and medical research and training\n- issue guidelines on and advise the community on matters related to health and medical research\n- advise the community on ethical issues relating to health\n\n### Outcome 3: Integrity of research\nMaintain a strong integrity framework underpinning rigorous and ethical research, and promoting community trust. [AR p.15](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=15) [[CP p.15](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=15)]\n\n**Key activities:**\n- fund health and medical research and training\n- issue guidelines on and advise the community on matters related to health and medical research\n- advise the community on ethical issues relating to health\n\n## Values and principles\n\n_NHMRC’s mission and purposes_\n\n- Investment\n- Translation\n- Integrity\n\n## What they will measure themselves on this year (targets from 2025-26 corporate plan)\n\n| Code | Measure | Target | Source |\n|---|---|---|---|\n| CCE01 | Grants are awarded, based on expert peer review, distribution of the value of new grants across the full spectrum of health and medical research, and include national, state and territory and community priorities | Target/s Methodology Measure type Reporting years | [CP p.47](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=47)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=47) |\n| CCE02 | More than 5% of NHMRC’s annual budget is awarded to research that aims to improve health outcomes for Aboriginal and Torres Strait Islander people | Quantitative assessment of the number of grants, amount of funding awarded and funded rates by gender, and whether measures have been applied to reduce gender disparities | [CP p.47](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=47)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=47) |\n| CCE03 | Research is conducted responsibly, ethically and with integrity in Australia | Compliance with regulatory requirements under the Research Involving Human Embryos Act 2002 | [CP p.49](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=49)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=49) |\n| CCE04 | Research involving human embryos is conducted ethically and legally in accordance with appropriate licence conditions | Qualitative assessment from inspections and six-monthly reports | [CP p.49](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=49)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf#page=49) |\n\n## How they performed last year (results from 2024-25 annual report)\n\n| Code | Measure | Result | Status | Source |\n|---|---|---|---|---|\n| CCE01 | Grants are awarded, based on expert peer review, distribution of the value of new grants across the full spectrum of health and medical research, and include national, state and territory and community priorities | 8.9% of new grants awarded (by value) to research on health in Aboriginal and Torres Strait Islander people | Achieved | [AR p.19](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=19)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=19) |\n| CCE02 | More than 5% of NHMRC’s annual budget is awarded to research that aims to improve health outcomes for Aboriginal and Torres Strait Islander people | 4.4% of new grants were led by chief investigators of Aboriginal and/or Torres Strait Islander descent | Achieved | [AR p.19](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=19)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=19) |\n| CCE03 | Research is conducted responsibly, ethically and with integrity in Australia | Target met | Achieved | [AR p.19](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=19)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=19) |\n| CCE04 | Research involving human embryos is conducted ethically and legally in accordance with appropriate licence conditions | Target met | Achieved | [AR p.19](https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=19)(https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf#page=19) |", "strategy_overview_evidence_md": null, "internal_strategy_evidence_md": "# National Health and Medical Research Council - Commissioner of Complaints - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T22:22:01.003811+00:00\n**Entity ID**: B-001935\n**Entity type**: Statutory Body\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: https://www.nhmrc.gov.au/about-us/leadership-and-governance/council\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| annual-reports | 5 |\n| corporate-plans | 5 |\n| other-pdfs | 5 |\n| pages | 42 |\n| reviews | 1 |\n| strategies | 2 |\n\n## Executive Readout\n\n### Purpose\n\n- Figure 2 NHMRC purposes mapped against PBS program objectives[1]\nNHMRC PURPOSE PBS PROGRAM OBJECTIVE\nSupporting high quality health and medical research\nFund high quality\nhealth and medical Boosting dementia research\nresearch and build\nresearch capability Streamlining grant assessment and management processes and\ndeveloping a nationally consistent approach to clinical trials\nSupport the Supporting the translation of health and medical research\ntranslation of health\nand medical\nresearch into better Streamlining grant assessment and management processes and\nhealth outcomes developing a nationally consistent approach to clinical trials\nPromoting the highest ethical standards in health\nPromote the highest\nand medical research\nethical standards in\nhealth and medical\nStreamlining grant assessment and management processes and\nresearch\n Source: `corporate-plans/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf)`\n- [Page 49]\nPart 3: Annual performance statements\nTable 5: NHMRC’s strategic themes, functions and purposes\nTheme Investment Translation Integrity\nFund high-quality health Support the translation of Promote the highest\nand medical research and health and medical research standards of ethics and\nFunction\nbuild research capability into better health outcomes integrity in health and\nmedical research\nCreate knowledge and Drive the translation Maintain a strong integrity\nbuild research capability of health and medical framework underpinning\nthrough investment in the research into public health rigorous and ethical\nPurpose highest-quality health and systems and clinical research and promoting\nmedical research and the practice and support community trust\nbest researchers the commercialisation of\nresearch discoveries\nSummary of results\n Source: `annual-reports/2023-24.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf)`\n- [Page 99]\nAnnual Report of the National Health and Medical Research Council 2016–2017 89\ntnemnorivne\ngnitarepo\n3\nTRAP\nRisk management\nIn support of its mission and strategic objectives, NHMRC is committed to managing its risks both\nstrategically and systematically.\n Source: `annual-reports/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf)`\n- Figure 4 NHMRC purposes mapped to portfolio program objectives\nNHMRC PURPOSE PORTFOLIO OBJECTIVES\nSupporting high quality health and medical research\nFund high quality\nhealth and medical Boosting dementia research\nresearch and build\nresearch capability\nStreamlining grant assessment and management processes and\ndeveloping a nationally consistent approach to clinical trials\nSupporting the translation of health and medical research\nSupport the\ntranslation of health\nand medical\nStreamlining grant assessment and management processes and\nresearch into better\ndeveloping a nationally consistent approach to clinical trials\nhealth outcomes\nPromoting the highest ethical standards in health and medical research\nPromote the highest\nethical standards\nin health and\nStreamlining grant assessment and management processes and\nmedical research\ndeveloping a nationally consistent approach to clinical trials\n Source: `annual-reports/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf)`\n\n### Role and Functions\n\n- [Page 170]\n7\nAppendix 3: List of requirements\nAppendix 3: List of requirements\nPGPA Rule\nPart of report Description Requirement Page\nreference\n17AD(g) Letter of transmittal\n17AI Letter of A copy of the letter of transmittal signed Mandatory 6\ntransmittal and dated by accountable authority on\ndate final text approved, with statement\nthat the report has been prepared in\naccordance with section 46 of the Act\nand any enabling legislation that specifies\nadditional requirements in relation to\nthe annual report\n17AD(h) Aids to access\n17AJ(a) Contents Table of contents (print only) Mandatory 4–5\n17AJ(b) Appendices Alphabetical index (print only) Mandatory 186\n17AJ(c) Appendices Glossary of abbreviations and acronyms Mandatory 178\n17AJ(d) Appendices List of requirements Mandatory 170\n17AJ(e) Publication Details of contact officer Mandatory 3\ndetails\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n- Support an Australian health system that is research-led, evidence-based, efficient and\nsustainable.*\nTarget/s Methodology Reporting\nyears\n8 Develop and/or Qualitative assessment of NHMRC’s 2024–25\napprove public and role in developing, updating and/\n2025–26\nenvironmental health or approving guidelines that are\nand clinical practice timely, are based on a review of the 2026–27\nguidelines.* available evidence, follow transparent\n2027–28\ndevelopment and decision-making\nprocesses, and will promote health,\nprevent harm, encourage best practice\nand reduce waste.\n*This performance measure/target is included in the Portfolio Budget Statements.\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Research is conducted responsibly, ethically and with integrity in Australia.*\nTarget/s Methodology Reporting\nyears\n10 Research integrity Quantitative assessment using 2024–25\nmatters are managed NHMRC’s annual survey of\n2025–26\nappropriately by Administering Institutions (Institutional\nAdministering Annual Compliance Report) to ensure 2026–27\nInstitutions in line with that the Code and its supporting\n2027–28\nthe requirements of the guides have been implemented in\nAustralian Code for the institutional processes, and qualitative\nResponsible Conduct of analysis of Australian Research\nResearch (the code).* Integrity Committee reviews of the\nprocesses used by Administering\nInstitutions to conduct integrity\ninvestigations in line with the\nrequirements of the Code.\n*This performance measure/target is included in the Portfolio Budget Statements.\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Table 2 Portfolio Budget Statement – NHMRC expenses and resources\nOutcome 1: Improved health and medical knowledge,\nincluding through funding research, translating Actual\nresearch findings into evidence-based clinical Budget* Expenses Variation\npractice, administering legislation governing research, 2014-15 2014-15 2014-15\nissuing guidelines and advice for ethics in health and $’000 $’000 $’000\nthe promotion of public health. (a) (b) (a)-(b)\nProgramme 1.1: Health and Medical Research\nAdministered expenses\nOrdinary Annual Services (Appropriation Act No.\n Source: `annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)`\n- Table 2 Portfolio Budget Statement – NHMRC expenses and resources\nExpenses for Outcome 1\nOutcome 1: Improved health and medical knowledge, Actual\nincluding through funding research, translating research Budget* Expenses Variation\nfindings into evidence-based clinical practice, administering 2015–16 2015–16 2015–16\nlegislation governing research, issuing guidelines and advice for $’000 $’000 $’000\nethics in health and the promotion of public health. (a) (b) (a)-(b)\nProgramme 1.1: Health and Medical Research\nAdministered expenses\nOrdinary Annual Services (Appropriation Act No.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- Goal 4: Administer the Research Involving Human Embryos Act 2002 and the Prohibition of Human\nCloning for Reproduction Act 2002\nTarget 1 Stakeholders demonstrate continued understanding of regulatory requirements work ongoing\nTarget 2 implement new processes to decrease the burden of red tape on businesses work ongoing\nOutcome 4: D uring 2015–16 the Embryo Research Licensing Committee has fulfilled its functions\nand, through NHMRC, continued to administer the legislation.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n\n### Strategic Priorities\n\n- [Page 5]\nContents\nMessage from the CEO 1\nStatement of Preparation 2\nIntroduction 3\nRequirements for the Corporate Plan 3\nAbout NHMRC 4\nCapability 5\nRisk oversight and management 7\nNHMRC’s purposes 8\nEnvironment within which NHMRC operates 12\nNHMRC’s strategic direction 15\nMajor health issues 15\nStrategy for health and medical research 17\nStrategic priorities 19\nInvestment 19\nTranslation 20\nIntegrity 21\nPerformance: how NHMRC will achieve its purposes 22\nKey activities and performance measures 24\nNational Health and Medical Research Council Corporate Plan 2016–2017 v\n Source: `corporate-plans/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf)`\n- [Page 5]\nContents\nMessage from the CEO 1\nStatement of preparation 2\nIntroduction 3\nRequirements for the Corporate Plan 3\nNHMRC’s purposes 4\nAbout NHMRC 6\nCapability 8\nRisk oversight and management 11\nEnvironment within which NHMRC operates 13\nNHMRC’s strategic direction 18\nMajor health issues 18\nStrategy for health and medical research 20\nStrategic priorities 22\nInvestment 22\nTranslation 23\nIntegrity 24\nPerformance: how NHMRC will achieve its purposes 25\nKey activities and performance measures 27\nAppendix 34\nNational Health and Medical Research Council Corporate Plan 2017–2018 iii\n Source: `corporate-plans/2017-18.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/4ba2e828-a6a9-4c84-beab-a45c39967b6e/upload_pdf/17293_nhmrc_corporate_plan_2017-18-web.pdf;fileType=application%2Fpdf)`\n- [Page 3]\nContents\nMessage from the CEO 3\nStatement of preparation 3\nNHMRC’s mission and purposes 4\nNHMRC’s strategic priorities 5\nStrategy for health and medical research 6\nKey activities 7\nInvestment 7\nTranslation 7\nIntegrity 8\nCorporate operations 8\nPerformance measures 9\nEnvironment, capability and risk 16\nNHMRC’s environment 16\nCapability 17\nRisk 19\n1\n Source: `corporate-plans/2018-19.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/77446457-0aed-405b-b234-73321c169df2/upload_pdf/corporate-plan-2018-2019.pdf;fileType=application%2Fpdf)`\n- [Page 3]\nContents\nAcknowledgement of Country 2\nMessage from the CEO 3\nStatement of preparation 5\nOverview 7\nPurposes 8\nLegislative context 9\nStrategy 10\nOverview 11\nNHMRC Council and committees 12\nStrategic priorities 14\nHealth priorities 15\nCooperation 16\nConsumers and community groups 17\nIndustry organisations 17\nGovernment and other research funders 17\nResearchers and research organisations 18\nOperating context 20\nGovernance and accountability 21\nEnvironment 21\nRisk oversight and management 22\nCapability 27\nActivities 30\nKey activities 31\nPerformance 34\nPerformance measures 35\nAppendix A: List of requirements 40\nNational Health and Medical Research Council 1\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- [Page 3]\nContents\nAcknowledgment of Country 4\nMessage from the CEO 5\nStatement of preparation 7\nNHMRC’s values 8\nOverview 9\nPurposes 10\nLegislative context 11\nStrategy 12\nOverview 13\nNHMRC Council and Committees 14\nStrategic priorities 16\nHealth priorities 18\nCooperation 20\nConsumers and community groups 21\nIndustry organisations 21\nGovernment relations and other research funders 21\nResearchers and research organisations 23\nOperating context 24\nGovernance and accountability 25\nEnvironment 26\nRisk oversight and management 28\nCapability 33\nActivities 38\nKey activities 40\nPerformance 44\nPerformance measures 46\nAppendix A: List of requirements 50\nNational Health and Medical Research Council | Corporate Plan 2025-26 3\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Table 7: Corporate Plan requirements\nLegislation\nRequirement Page(s)\nReference\nIntroduction\n• statement of preparation: a statement that the plan is prepared for\n16E(2) 5\nparagraph 35(1)(b) of the PGPA Act\nPGPA Rule\n• the reporting period for which the plan is prepared\n• the reporting periods covered by the plan\nPurposes 16E(2)\n8\nPGPA Rule\nStrategy for health and medical research 16(2)\n11\n• a national strategy for medical research and public health research NHMRC Act\nHealth priorities\n• the CEO’s assessment of the major national health issues that are 16(2)\nlikely to arise during the period 15\nNHMRC Act\n• the manner in which the CEO proposes to perform their functions\nin dealing with those issues during the period\n16E(2)\nCooperation 16\nPGPA Rule\nOperating context\n• environment 21\n16E(2)\n• risk oversight and management, including key risks and its 22\nmanagement PGPA Rule\n27\n• capability\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Table 1: NHMRC’s strategic priorities for 2024-2027\nStrategic priority Overview Planned actions in 2025–26\nSupport the Working with the Department Finalise and release the National Strategy\nNational Strategy of Health, Disability and within the next 12 months commencing\nAgeing to develop a new and with consultation on the draft National\ncohesive National Health and Strategy in the second half of 2025,\nMedical Research Strategy. including roundtables, workshops and\nwritten submissions.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Table 7: Corporate plan requirements\nRequirement Legislation reference Page(s)\nIntroduction 16E(2) PGPA Rule 7\n• statement of preparation: a statement that the plan is prepared\nfor paragraph 35(1)(b) of the PGPA Act\n• the reporting period for which the plan is prepared\n• the reporting periods covered by the plan\nPurposes 16E(2) PGPA Rule 10–11\nStrategy 16(2) NHMRC Act 16-17\n• a national strategy for medical research and public health research\nHealth priorities 16(2) NHMRC Act 18-19\n• the CEO’s assessment of the major national health issues that are\nlikely to arise during the period\n• the manner in which the CEO proposes to perform their functions\nin dealing with those issues during the period\nOperating context 16E(2) PGPA Rule\n• cooperation 20-23\n• subsidiaries (where applicable) N/A\n• environment 26\n• risk oversight, including key risks and its management 28-31\n• capability 33\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- [Page 6]\nLIST OF TABLES\nTable 1 NHMRC research funding 2014–15 22\nTable 2 Portfolio Budget Statement – NHMRC expenses and resources 34\nTable 3 Administration of NHMRC funding by research sector 35\nTable 4 Funding by broad research area 36\nTable 5 Breakdown of year duration for 2014 applications 37\nTable 6 Research scheme expenditure in the National Health Priority Areas, 2014–15 49\nTable 7 Inspections under the RIHE and PHCR Acts 72\nTable 8 Deliverables, reference point and performance indicators, 2014–15 78\nTable 9 Complaints about NHMRC funding or grant processes, 2014–15 83\nTable 10 Freedom of Information requests, 2014–15 87\nTable 11 Staff distribution by office as at 30 June 2015 89\nTable 12 Employee classification by gender 89\nTable 13 Employment status as at 30 June 2015 90\nTable 14 Consultancy contract expenditure from 2011–12 to 2014–15 94\n Source: `annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)`\n- [Page 43]\nTable 5: Links between key activities and priorities\nStrategic Health Capability\npriority priority priority\nKey activity\nNational Health and Medical Research Council | Corporate Plan 2025-26 43\nygetartS\nlanoitaN\neht troppuS\nAERM\ndna\nFFRM\neht\nesinomraH\nweiver\nreep\nni ecnellecxe\nniatniaM\ntnemevlovni\nremusnoc\nnoipmahC\nhcraeser\nhtlaeh\nni\nytiuqe\ndebmE\nytirgetni\nhcraeser\nni ecnedfinoc\nretsloB\nnoitasilaicremmoc\ndna noitalsnart\nretsoF\nhtlaeh\ncilbup\ndna\nnoitneverp\netomorP\nhtlaeh\nrednalsI\ntiartS\nserroT\ndna\nlanigirobA\nhtlaeh\nni ecnegilletni\nlaicfiitrA\nseicnegreme\ndna\nstaerht\nhtlaeh\ngnigremE\nsnoitidnoc\nmret-gnol\nelpitluM\nytilibapac\natad dna\nTCI\nesimitpO\nmroftalp\nstnarg\nerihppaS\neht hserfeR\nytilibaniatsus\nlaicnanfi\nesimitpO\nhcaertuo\ndna\nnoitacinummoc\necnahnE\nerutluc\nnoitavonni\nna\ndliuB\nResearch strategy and policy               \nGrant opportunities            \n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n\n## KPIs, Targets, and Where They Are At\n\n- Support an Australian health system that is research-led, evidence-based, efficient and\nsustainable.*\nTarget/s Methodology Reporting\nyears\n8 Develop and/or Qualitative assessment of NHMRC’s 2024–25\napprove public and role in developing, updating and/\n2025–26\nenvironmental health or approving guidelines that are\nand clinical practice timely, are based on a review of the 2026–27\nguidelines.* available evidence, follow transparent\n2027–28\ndevelopment and decision-making\nprocesses, and will promote health,\nprevent harm, encourage best practice\nand reduce waste.\n*This performance measure/target is included in the Portfolio Budget Statements.\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- [pages 39,40,41,42,43,44]\nand clinical practice timely, are based on a review of the 2026–27\nguidelines.* available evidence, follow transparent\n2027–28\ndevelopment and decision-making\nprocesses, and will promote health,\nprevent harm, encourage best practice\nand reduce waste.\n*This performance measure/target is included in the Portfolio Budget Statements.\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Research is conducted responsibly, ethically and with integrity in Australia.*\nTarget/s Methodology Reporting\nyears\n10 Research integrity Quantitative assessment using 2024–25\nmatters are managed NHMRC’s annual survey of\n2025–26\nappropriately by Administering Institutions (Institutional\nAdministering Annual Compliance Report) to ensure 2026–27\nInstitutions in line with that the Code and its supporting\n2027–28\nthe requirements of the guides have been implemented in\nAustralian Code for the institutional processes, and qualitative\nResponsible Conduct of analysis of Australian Research\nResearch (the code).* Integrity Committee reviews of the\nprocesses used by Administering\nInstitutions to conduct integrity\ninvestigations in line with the\nrequirements of the Code.\n*This performance measure/target is included in the Portfolio Budget Statements.\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Support an Australian health system that is research-led, evidence based, efficient and\nsustainable.*\nTarget Methodology Measure type Reporting years\n8 Develop and/or Review of NHMRC records to identify Output 2025–26\napprove public and all CEO approvals/issuances in the 2026–27\nenvironmental health reporting period and NHMRC Council\n2027–28\nand clinical practice records that also demonstrate that\nguidelines.* Guidelines are developed consistent 2028–29\nwith NHMRC standards for guidelines\nunder subsection 7(1) of the NHMRC\nAct 1992, as well as records that\ndemonstrate progress of guidelines\nunder development.\n*This performance measure/target is included in the Portfolio Budget Statements.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Funding is categorised as\nthat will provide better ‘Indigenous health research’ through 2026–27\nhealth outcomes for a combination of Indigenous Research\n2027–28\nAboriginal and Torres Excellence Criteria assessment and\nStrait Islander people.* reviewing each funded grant against\na range of investigator provided data\nclassifications including fields of\nresearch, keywords, grant titles and\nmedia summaries.\n*This performance measure/target is included in the Portfolio Budget Statements, but has been\nmodified here to focus on new grants awarded only (previously the target included expenditure\non all active grants, as well as new grants awarded).\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Table 7: Corporate Plan requirements\nLegislation\nRequirement Page(s)\nReference\nIntroduction\n• statement of preparation: a statement that the plan is prepared for\n16E(2) 5\nparagraph 35(1)(b) of the PGPA Act\nPGPA Rule\n• the reporting period for which the plan is prepared\n• the reporting periods covered by the plan\nPurposes 16E(2)\n8\nPGPA Rule\nStrategy for health and medical research 16(2)\n11\n• a national strategy for medical research and public health research NHMRC Act\nHealth priorities\n• the CEO’s assessment of the major national health issues that are 16(2)\nlikely to arise during the period 15\nNHMRC Act\n• the manner in which the CEO proposes to perform their functions\nin dealing with those issues during the period\n16E(2)\nCooperation 16\nPGPA Rule\nOperating context\n• environment 21\n16E(2)\n• risk oversight and management, including key risks and its 22\nmanagement PGPA Rule\n27\n• capability\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Target Methodology Measure type Reporting years\n3 Better matching of peer Analysis of the peer review Efficiency and 2025–26\nreviewers to applications, process, including level of self- effectiveness 2026–27\nimproving application- reported suitability matching of\n2027–28\ncentric peer review in peer reviewers to applications,\napplicable schemes, and feedback from reviewers and 2028–29\nreduced burden on peer measurement of time spent on\nreviewers. peer review.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Target Methodology Measure type Reporting years\n5 3.4% of NHMRC’s annual Quantitative assessment of the Output 2025–26\ngrants awarded to lead percentage of new grants awarded 2026–27\nchief investigators of in the financial year to lead chief\n2027–28\nAboriginal and Torres investigators of Aboriginal and/or\nStrait Islander descent.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Target Methodology Measure type Reporting years\n7 Gender inequities Quantitative assessment of the Output and 2025–26\nin NHMRC funding number of grants, amount of effectiveness 2026–27\noutcomes are reduced. funding awarded and funded rates\n2027–28\nby gender, and whether measures\nhave been applied to reduce 2028–29\ngender disparities.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Research is conducted responsibly, ethically and with integrity in Australia.*\nTarget Methodology Measure type Reporting years\n11 Research integrity Quantitative assessment using Effectiveness 2025–26\nmatters are managed NHMRC’s annual survey of 2026–27\nappropriately by Administering Institutions\n2027–28\nAdministering (Institutional Annual Compliance\nInstitutions in line with Report) to ensure that the Code 2028–29\nthe requirements of and its supporting Guides have\nthe Australian Code been implemented in institutional\nfor the Responsible processes and that required\nConduct of Research.* notifications of integrity matters\nare made in line with the NHMRC\nResearch Integrity and Misconduct\nPolicy 2019.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Target Methodology Measure type Reporting years\n12 Compliance with Qualitative assessment from Effectiveness 2025–26\nregulatory requirements inspections and six-monthly reports 2026–27\nunder the Research is used to calculate the number and\n2027–28\nInvolving Human type of incidents of non-compliance\nEmbryos Act 2002. with licence conditions by each licence 2028–29\nholder in the period, as well as how\nquickly and effectively any actions to\nredress non-compliance (as required\nby the regulator) are actioned by the\nlicence holder.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Table 7: Corporate plan requirements\nRequirement Legislation reference Page(s)\nIntroduction 16E(2) PGPA Rule 7\n• statement of preparation: a statement that the plan is prepared\nfor paragraph 35(1)(b) of the PGPA Act\n• the reporting period for which the plan is prepared\n• the reporting periods covered by the plan\nPurposes 16E(2) PGPA Rule 10–11\nStrategy 16(2) NHMRC Act 16-17\n• a national strategy for medical research and public health research\nHealth priorities 16(2) NHMRC Act 18-19\n• the CEO’s assessment of the major national health issues that are\nlikely to arise during the period\n• the manner in which the CEO proposes to perform their functions\nin dealing with those issues during the period\nOperating context 16E(2) PGPA Rule\n• cooperation 20-23\n• subsidiaries (where applicable) N/A\n• environment 26\n• risk oversight, including key risks and its management 28-31\n• capability 33\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- INVESTMENT\nGoal 1: Support high quality health and medical research\nTarget 1 Allocate 50 per cent of total Medical research endowment Account (MreA) funding annually to Achieved\nNHMrC’s Project Grant scheme\nTarget 2 report annually on funding by broad research area, National Health Priority Areas and Australian Achieved\nGovernment priorities\nTarget 3 examine the role of philanthropic funding work ongoing\nTarget 4 run at least one Targeted Call for research annually work ongoing\nTarget 5 Periodic review of established funding schemes Achieved\nTarget 6 Completed reviews are presented to research Committee for consideration Achieved\nOutcome 1: N HMRC continued to support high quality health and medical research throughout\n2015–16.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- Goal 3: Boost dementia research\nTarget 1 establish a National institute for Dementia research Achieved\nTarget 2 Support the Clem Jones Centre for Ageing Dementia research Achieved\nTarget 3 work with the Australian research Council to build dementia research capacity Achieved\nTarget 4 Support large scale research in priority areas for dementia research Achieved\nOutcome 3: The Boosting Dementia Initiative is delivering on its commitment to enhance research\non dementia and to translate the results into policy and practice.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| $2.8 million, 2.8 million | Table 25 Departmental financial performance\n30 June 2017 30 June 2016\n($’000) ($’000)\nOperating expenses 42,658 41,470\nOwn-source income (2,266) (1,248)\nGains (108) (430)\nNet cost of services 40,284 39,792\nRevenue from government (37,442) (40,237)\nOperating (deficit) / surplus (2,842) 445\nChange in asset revaluation surplus (124) 51\nTotal operating (deficit) / surplus (2,966) 496\nNHMRC’s operating result for 2016–17 was a deficit of $2.8 million. | `annual-reports/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf)` |\n| 11 Staff | [Page 6]\nLIST OF TABLES\nTable 1 NHMRC research funding 2014–15 22\nTable 2 Portfolio Budget Statement – NHMRC expenses and resources 34\nTable 3 Administration of NHMRC funding by research sector 35\nTable 4 Funding by broad research area 36\nTable 5 Breakdown of year duration for 2014 applications 37\nTable 6 Research scheme expenditure in the National Health Priority Areas, 2014–15 49\nTable 7 Inspections under the RIHE and PHCR Acts 72\nTable 8 Deliv | `annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)` |\n| $7.0 million, 7.0 million | [Page 131]\nAnnual Report of the National Health and Medical Research Council 2016–2017 121\ntroper\nLaicnanif\n5\nTRAP\nThe decrease in Administered expenses ($7.0 million) largely reflects delays in grants awarded from the\nBoosting Dementia Research budget measure and lower than expected awards from previous rounds of\nPartnership Projects, Hearing Loss Prevention Program and Program Grants. | `annual-reports/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf)` |\n| $891,000 | [Page 156]\n6\nOFFICIAL Financial performance\nNote 5.1 Funding\nNote 5.1A Annual appropriations (‘Recoverable GST exclusive’)\nAppropriation\nSection 74 applied\nAnnual PGPA Act Total (current and\nappropriation1 receipts appropriation prior years) Variance2\nAnnual appropriations for 2025 $’000 $’000 $’000 $’000 $’000\nDepartmental\nOrdinary annual services 38,248 21,679 59,927 (53,510) 6,417\nCapital budget 190 - 190 (190) -\nTotal departmental 38,438 21,6 | `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)` |\n| $13.2\nmillion, $7.5 million, $5.7 million, $0.6 million, $0.5\nmillion, $2 million | Figure 2 Medical research endowment account: new grant commitments, appropriations,\npayments and balance\n21\nAnnual Report of the National Health and Medical Research Council 2014–2015\nNOILLIM\n$\n1,000\n900\n800\n700\n600\n500\n400\n300\n200\n100\n0\n2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 2013–14 2014–15\nFINANCIAL YEAR\nNew Grant Commitments Revenue (Appropriation & Other Receipts)\nGrant Payments MREA Balance\nIn | `annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)` |\n| $13.2\nmillion, $7.5 million, $5.7 million, $0.6 million, $0.5\nmillion, $2 million | [pages 29,30,31,32]\nFINANCIAL YEAR\nNew Grant Commitments Revenue (Appropriation & Other Receipts)\nGrant Payments MREA Balance\nIn 2014-15 NHMRC also administered grant programs for activities related to dementia research ($13.2\nmillion, including $7.5 million for Boosting Dementia Research and $5.7 million for dementia related\ncollaborative and partnership research centres), rheumatic fever ($0.6 million), anti-venom research ($0.5\nmillion) and pr | `annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)` |\n| $8.8 million, $2.8 million, $6.0 million, $0.5 million, $2 million, 8.8 million | Figure 2 Medical Research Endowment Account: new grant commitments, revenue,\ngrant payments and the MREA balance\n9\nNOILLIM\n$\n1,000\n900\n800\n700\n600\n500\n400\n300\n200\n100\n0\n200 6-07 200 7-08 200 8-09 200 9-10 201 0-11 201 1-12 201 2-13 201 3-14 201 4-15 201 5-16\nFINANCIAL YEAR\nNew Grant Commitments Grant Payments\nRevenue (Appropriation & Other Receipts) MREA Balance\nIn 2015–16, NHMRC also administered grant programs for activities related to dementia | `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)` |\n| $2.4 million, $2.2 million, $0.1 million, 2.4 million, 2.2 million | Figure 8: Medical Research Endowment Account, 2014–15 to 2023–24\n1,600\n1,400\n1,200\n1,000\n800\n600\n400\n200\n0\n2014–15 2015–16 2016–17 2017–18\nFinancial year\nNew grant commitments Revenue (appropriation & other receipts)\nGrant payments MREA balance\nnoillim\n$\nPart 1: Overview\n2018–19 2019–20 2020–21 2021–22 2022–23 2023–24\nIn 2023–24, NHMRC also administered $2.4 million outside the MREA for the provision\nof research evidence for clinical practice and | `annual-reports/2023-24.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf)` |\n| $60.4 million, $46.4\nmillion, $36.3 million, $14.0 million, $14.5 million, 60.4 million | Revenue impacts\nDepartmental revenue of $60.4 million includes annual appropriation revenue of $46.4\nmillion (2022–23 $36.3 million) and funding received from the Department of Health and\nAged Care for the administration of the Medical Research Future Fund (MRFF) grant\nprogram and other services of $14.0 million (2022–23 $14.5 million). | `annual-reports/2023-24.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf)` |\n| 50 per cent | INVESTMENT\nGoal 1: Support high quality health and medical research\nTarget 1 Allocate 50 per cent of total Medical research endowment Account (MreA) funding annually to Achieved\nNHMrC’s Project Grant scheme\nTarget 2 report annually on funding by broad research area, National Health Priority Areas and Australian Achieved\nGovernment priorities\nTarget 3 examine the role of philanthropic funding work ongoing\nTarget 4 run at least one Targeted Call fo | `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)` |\n\n## Key Achievements\n\n- [Page 87]\nCORPORATE REPORTING PART 3\nQualitative Reference point\ndeliverables or target Performance\nPeriodic review Completed Public consultation on elements of the Project Grants scheme\nof established reviews are\nfunding presented NHMRC CEO Professor Warwick Anderson AM called for\nschemes to to Research submissions on the following elements of the Project Grants\ndetermine Committee for assessment process and funding rules:\nstrengths and consideration,\n• ‘not-for-further consideration’ and applicant response steps\nidentify where and\nimprovements implemented • duration of Project Grants funding.\ncan be made according to\nestablished The consultation opened on 8 December 2014 and closed on\ntimelines 27 March 2015.\n Source: `annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)`\n- [pages 36,37,38,39,40]\niority-driven research through:\n» undertaking at least two dementia-focused grant rounds with outcomes\nannounced by December 2017\n» finalising arrangements with Vietnam for a workshop and bilateral call for\ngrant applications by December 2017\n» seeking a report from CRE in Infectious Disease Emergency Response\nResearch on research priority setting\n» establishing a Scientific Advisory Panel to assess the Northern Australia\nTropical Disease Collaborative Research Program’s progress against\nmilestones on a bi-annual basis.\n• Call for applications through the TCR program following consultation and\ndiscussion with the Department of Health, AHMAC, NHMRC Council and\nPrincipal Committees and community and professional groups.\n Source: `corporate-plans/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf)`\n- AMRAB has delivered the inaugural Australian Medical Research and\nInnovation Strategy 2016–2021 (the Strategy) and the accompanying Australian\nMedical Research and Innovation Priorities 2016–2018 (the Priorities) to the Minister\nfor Health and Aged Care, announced by the Government in November 2016.9\nThe Strategy emphasises the complementary roles of the MRFF and NHMRC, and\nhighlights opportunities for possible future collaboration.\n Source: `corporate-plans/2017-18.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/4ba2e828-a6a9-4c84-beab-a45c39967b6e/upload_pdf/17293_nhmrc_corporate_plan_2017-18-web.pdf;fileType=application%2Fpdf)`\n- Research is conducted responsibly, ethically and with integrity in Australia.*\nTarget/s Methodology Reporting\nyears\n10 Research integrity Quantitative assessment using 2024–25\nmatters are managed NHMRC’s annual survey of\n2025–26\nappropriately by Administering Institutions (Institutional\nAdministering Annual Compliance Report) to ensure 2026–27\nInstitutions in line with that the Code and its supporting\n2027–28\nthe requirements of the guides have been implemented in\nAustralian Code for the institutional processes, and qualitative\nResponsible Conduct of analysis of Australian Research\nResearch (the code).* Integrity Committee reviews of the\nprocesses used by Administering\nInstitutions to conduct integrity\ninvestigations in line with the\nrequirements of the Code.\n*This performance measure/target is included in the Portfolio Budget Statements.\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Support an Australian health system that is research-led, evidence based, efficient and\nsustainable.*\nTarget Methodology Measure type Reporting years\n8 Develop and/or Review of NHMRC records to identify Output 2025–26\napprove public and all CEO approvals/issuances in the 2026–27\nenvironmental health reporting period and NHMRC Council\n2027–28\nand clinical practice records that also demonstrate that\nguidelines.* Guidelines are developed consistent 2028–29\nwith NHMRC standards for guidelines\nunder subsection 7(1) of the NHMRC\nAct 1992, as well as records that\ndemonstrate progress of guidelines\nunder development.\n*This performance measure/target is included in the Portfolio Budget Statements.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Research is conducted responsibly, ethically and with integrity in Australia.*\nTarget Methodology Measure type Reporting years\n11 Research integrity Quantitative assessment using Effectiveness 2025–26\nmatters are managed NHMRC’s annual survey of 2026–27\nappropriately by Administering Institutions\n2027–28\nAdministering (Institutional Annual Compliance\nInstitutions in line with Report) to ensure that the Code 2028–29\nthe requirements of and its supporting Guides have\nthe Australian Code been implemented in institutional\nfor the Responsible processes and that required\nConduct of Research.* notifications of integrity matters\nare made in line with the NHMRC\nResearch Integrity and Misconduct\nPolicy 2019.\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- BUSINESS PLANNING\nThe 2014–15 Annual Business Plan operationalised the Strategic Plan 2013–15 and the Health Portfolio\nBudget Statement for NHMRC 2014–15, by setting out what each branch and section was expected to\ndeliver to ensure the achievement of NHMRC’s strategic objectives.\n Source: `annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)`\n- INVESTMENT\nGoal 1: Support high quality health and medical research\nTarget 1 Allocate 50 per cent of total Medical research endowment Account (MreA) funding annually to Achieved\nNHMrC’s Project Grant scheme\nTarget 2 report annually on funding by broad research area, National Health Priority Areas and Australian Achieved\nGovernment priorities\nTarget 3 examine the role of philanthropic funding work ongoing\nTarget 4 run at least one Targeted Call for research annually work ongoing\nTarget 5 Periodic review of established funding schemes Achieved\nTarget 6 Completed reviews are presented to research Committee for consideration Achieved\nOutcome 1: N HMRC continued to support high quality health and medical research throughout\n2015–16.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- [Page 37]\nAnnual Report of the National Health and Medical Research Council 2015–2016\nTrOPer\neCNAMrOfreP\n2\nTRAP\nTRANSLATION\nGoal 3: Develop public and environmental health and clinical advice\nTarget 1 Approve high quality clinical guidelines prepared by third parties Achieved\nTarget 2 Develop guidelines that address clinical, public and environmental health topics Achieved\nTarget 3 report on the quality of Australian clinical practice guidelines work ongoing\nTarget 4 Progress a new guideline development standard and methodology work ongoing\nOutcome 3: N HMRC continues to maintain its leadership role in the development and dissemination\nof public and environmental health and clinical advice.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- Goal 2: Strengthen process for managing research misconduct\nTarget 1 Prevent research misconduct and investigate complaints work ongoing\nTarget 2 Lead revision of the Australian Code for the Responsible Conduct of Research, 2007 work ongoing\nTarget 3 Undertake public consultation on a draft of the Australian Code for the Responsible Conduct of Research work ongoing\nTarget 4 revise the NHMRC Policy on Misconduct Related to NHMRC-funded Research work ongoing\nOutcome 2: N HMRC has made substantial progress toward supporting high ethical standards in\nhealth and medical research through strengthening the process for managing research\nmisconduct.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- Goal 3: Continue review of research ethics standards and guidelines\nTarget 1 ensure statements, codes and guidelines remain up-to-date and reflect best practice work ongoing\nTarget 2 review Section 3 of the National Statement on Ethical Conduct in Human research work ongoing\nTarget 3 review Ethical Guidelines on the Use of Assisted Reproductive Technology in Clinical Practice and work ongoing\nResearch\nTarget 4 Complete the Ethical Guidelines for Organ Transplantation from Deceased Donors Achieved\nTarget 5 Undertake public consultation on the development of Aboriginal and Torres Strait Islander Research work ongoing\nEthics Guidelines\nOutcome 3: S ignificant progress has been achieved with the review of research ethics standards\nand guidelines, many of which are associated with highly sensitive and complex issues.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- [Page 79]\nAnnual Report of the National Health and Medical Research Council 2015–2016\nTrOPer\neCNAMrOfreP\n2\nTRAP\nTable 17 NHMRC commitments to research translation focussed funding programs\nGrant purpose Amount\nBuild Capacity $280,934,020\nCreate Knowledge $393,280,485\nTranslate Research $191,474,992\nTotal $865,689,498\nTarget 7: Report on the percentage of Project Grants with an innovation category\nscore of five or more\nCorporate Plan Report annually on the percentage of Project Grants awarded each year\nwith a ‘significance and/or innovation’ category score of five or more, to Achieved\nhighlight the proportion of grants that foster innovation.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n\n## Key Issues, Risks, and Recommendations\n\n- [Page 172]\n7\nAppendix 3: List of requirements\nPGPA Rule\nPart of report Description Requirement Page\nreference\n17AD(d) Management and accountability\nCorporate governance\n17AG(2)(a) Part 4 Information on compliance with section 10 Mandatory 6, 112-113\n(fraud systems)\n17AG(2)(b)(i) Letter of Certification by accountable authority Mandatory 6\ntransmittal that fraud risk assessments and fraud\ncontrol plans have been prepared\n17AG(2)(b)(ii) Letter of Certification by accountable authority Mandatory 6\ntransmittal that appropriate mechanisms for\npreventing, detecting incidents of,\ninvestigating or otherwise dealing with,\nand recording or reporting fraud that\nmeet the specific needs of the entity\nare in place\n17AG(2)(b)(iii) Letter of Certification by accountable authority Mandatory 6\ntransmittal that all reasonable measures have been\ntaken to deal appropriately with fraud\nrelating to the entity\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n- [Page 184]\n7\nAppendix 5: List of figures and tables\nList of tables\nTable Title Page\nTable 1 NHMRC’s health priorities for the 2024–2027 triennium 18\nTable 2 NHMRC expenditure on research on major health issues, 2020–21 19\nto 2024–25\nTable 3 Summary of NHMRC’s new funding commitments, 2024–25 26\nTable 4 Criteria used to determine NHMRC performance 58\nTable 5 NHMRC expenditure by broad research area, 2020–21 to 2024–25 60\nTable 6 New grants awarded in 2023–24 and 2024–25 led by chief 66\ninvestigators who self-identified as being of Aboriginal and/or\nTorres Strait Islander descent\nTable 7 NHMRC Council Members, 2024–25 95\nTable 8 NHMRC Audit and Risk Committee, 2024–25 110\nTable 9 NHMRC freedom of information requests and reviews, 2024–25 114\nTable 10 Reportable consultancy contracts, 2024–25 119\nTable 11 Organisations receiving amounts under a reportable consultancy 119\ncontract, 2024–25\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n- [Page 5]\nContents\nMessage from the CEO 1\nStatement of Preparation 2\nIntroduction 3\nRequirements for the Corporate Plan 3\nAbout NHMRC 4\nCapability 5\nRisk oversight and management 7\nNHMRC’s purposes 8\nEnvironment within which NHMRC operates 12\nNHMRC’s strategic direction 15\nMajor health issues 15\nStrategy for health and medical research 17\nStrategic priorities 19\nInvestment 19\nTranslation 20\nIntegrity 21\nPerformance: how NHMRC will achieve its purposes 22\nKey activities and performance measures 24\nNational Health and Medical Research Council Corporate Plan 2016–2017 v\n Source: `corporate-plans/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf)`\n- [Page 5]\nContents\nMessage from the CEO 1\nStatement of preparation 2\nIntroduction 3\nRequirements for the Corporate Plan 3\nNHMRC’s purposes 4\nAbout NHMRC 6\nCapability 8\nRisk oversight and management 11\nEnvironment within which NHMRC operates 13\nNHMRC’s strategic direction 18\nMajor health issues 18\nStrategy for health and medical research 20\nStrategic priorities 22\nInvestment 22\nTranslation 23\nIntegrity 24\nPerformance: how NHMRC will achieve its purposes 25\nKey activities and performance measures 27\nAppendix 34\nNational Health and Medical Research Council Corporate Plan 2017–2018 iii\n Source: `corporate-plans/2017-18.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/4ba2e828-a6a9-4c84-beab-a45c39967b6e/upload_pdf/17293_nhmrc_corporate_plan_2017-18-web.pdf;fileType=application%2Fpdf)`\n- Table 7: Corporate Plan requirements\nLegislation\nRequirement Page(s)\nReference\nIntroduction\n• statement of preparation: a statement that the plan is prepared for\n16E(2) 5\nparagraph 35(1)(b) of the PGPA Act\nPGPA Rule\n• the reporting period for which the plan is prepared\n• the reporting periods covered by the plan\nPurposes 16E(2)\n8\nPGPA Rule\nStrategy for health and medical research 16(2)\n11\n• a national strategy for medical research and public health research NHMRC Act\nHealth priorities\n• the CEO’s assessment of the major national health issues that are 16(2)\nlikely to arise during the period 15\nNHMRC Act\n• the manner in which the CEO proposes to perform their functions\nin dealing with those issues during the period\n16E(2)\nCooperation 16\nPGPA Rule\nOperating context\n• environment 21\n16E(2)\n• risk oversight and management, including key risks and its 22\nmanagement PGPA Rule\n27\n• capability\n Source: `corporate-plans/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf)`\n- Table 7: Corporate plan requirements\nRequirement Legislation reference Page(s)\nIntroduction 16E(2) PGPA Rule 7\n• statement of preparation: a statement that the plan is prepared\nfor paragraph 35(1)(b) of the PGPA Act\n• the reporting period for which the plan is prepared\n• the reporting periods covered by the plan\nPurposes 16E(2) PGPA Rule 10–11\nStrategy 16(2) NHMRC Act 16-17\n• a national strategy for medical research and public health research\nHealth priorities 16(2) NHMRC Act 18-19\n• the CEO’s assessment of the major national health issues that are\nlikely to arise during the period\n• the manner in which the CEO proposes to perform their functions\nin dealing with those issues during the period\nOperating context 16E(2) PGPA Rule\n• cooperation 20-23\n• subsidiaries (where applicable) N/A\n• environment 26\n• risk oversight, including key risks and its management 28-31\n• capability 33\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- Goal 2: Support the translation of health and medical research\nTarget 1 fund Partnerships for Better Health projects and centres work ongoing\nTarget 2 Promote the role of Advanced Health research and Translation Centres work ongoing\nTarget 3 Continue to address evidence-practice gaps work ongoing\nTarget 4 work with the Commonwealth, states and territories to identify issues of mutual concern work ongoing\nTarget 5 work with Australian Health Protection Principal Committee (AHPPC) to develop research preparedness work ongoing\nin response to infectious disease threats to health\nTarget 6 Publish an updated Statement on Consumer and Community Participation in Health and Medical Research work ongoing\nTarget 7 establish the Health Translation Advisory Committee Achieved\nTarget 8 Host the fourth research Translation Symposium Achieved\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- [Page 74]\nAnnual Report of the National Health and Medical Research Council 2015–2016 Annual Report of the National Health and Medical Research Council 2015–2016\nTrOPer\neCNAMrOfreP\n2\nTRAP\nGuideline Responsible organisation Description\nClinical practice Prostate Cancer Foundation These guidelines provide health\nguidelines: PSA Testing Australia and Cancer professionals access to evidence-based\nand Early Management of Council Australia recommendations for using the prostate\nTest-Detected Prostate specific antigen (PSA) blood test to assess\nCancer (recommendations) prostate cancer risk and manage test-\ndetected patients.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- In 2023–24, NHMRC funding for research in national and global priority areas included:\n• $2.3 million for Australian participation in antimicrobial resistance diagnostics and\nsurveillance research through the Joint Programming Initiative on Antimicrobial\nResistance\n• $3 million for Australian participation in research into climate change and health in the\nEast Asian region through the e-ASIA Joint Research Program\n• $2.5 million for Australian participation and collaboration in transnational research\nprojects on mechanisms of resilience and vulnerability to environmental challenges in\nmental health through the Network of European Funding for Neuroscience Research\n(NEURON)\n• $4.2 million for Australian participation in international collaborative research about\nthe clinical and cost-effectiveness and broader impact of healthcare treatments and\n Source: `annual-reports/2023-24.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf)`\n- [Page 87]\nPart 4: Operating environment\nTable 13: NHMRC Audit and Risk Committee, 2023–24\nNumber of\nTotal annual\nQualifications, meetings\nremuneration Additional\nName knowledge, skills or attended /\n(GST information\nexperience total number\ninclusive)\nof meetings\nIndependent accounting\nprofessional experience,\nMr Geoff Chartered Accountant and Independent\n4/4 $8,000\nKnuckey FCA Graduate of the Australian Chair\nInstitute of Company\nDirectors (GAICD)\nSkills and experience\nin the entity’s business\nProfessor\nand operating context, Member until\nMatthew 1/1 $1,530a\nincluding knowledge of 31 August 2023\nGillespie AM\nthe health and medical\nresearch sector\nSkills and experience\nin the entity’s business\nand operating context,\nincluding relevant\nknowledge of healthcare\nProfessor\npolicy and regulation.\n Source: `annual-reports/2023-24.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf)`\n- Member,\nAnthony 3/4 $0b\nMember with relevant full year\nLawler GAICD\nknowledge of performance\nreporting and knowledge\nof systems of internal\ncontrol and risk oversight\nand management; GAICD\nSkills and experience\nin the entity’s business\nProfessor and operating context,\nMember,\nEleanor including knowledge 4/4 $6,120a\nfull year\nMilligan of healthcare ethics,\norganisational culture and\ngovernance; GAICD\nRelevant knowledge of\nfinancial and performance\nMs Fran\nreporting, including Member,\nRaymond FCA 4/4 $6,120a\naccounting and audit full year\nFAICD, MBA\nstandards, Chartered\nAccountant and GAICD\na No GST was payable on this member’s remuneration.\nb Member declined payment for services rendered as a member of the Audit and Risk Committee.\n Source: `annual-reports/2023-24.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf)`\n- Reports by parliamentary committees\nThe following parliamentary inquiries and other independent inquiries reported in 2024–25\nand made recommendations relevant to NHMRC activities:\n• The Royal Commission into Defence and Veteran Suicide delivered its Final Report on\n9 September 2024, which made 122 recommendations for reform including reference to\nNHMRC’s role in funding health and medical research to support veteran’s health.\n• The independent COVID-19 Response Inquiry report was released on 29 October 2024,\nwith Action 23 including recommending developing dedicated ethical guidelines and\nprocesses for national health emergencies to enable rapid review in a changed risk\ncontext and enable real-time crisis-related research, overseen by NHMRC.\n• The Parliament of Western Australia Inquiry into support for health and medical\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n- [Page 109]\n4\nOperating environment\nDuring 2024–25, the Australian Government responded to the following parliamentary\ninquiries or independent inquiries, which had made recommendations relevant to areas of\nNHMRC activity:\n− The Government Response to the Royal Commission into Defence and Veteran\nSuicide was announced on 2 December 2024, which notes that NHMRC will consider\npriority-driven research grant opportunities focused on veteran health and wellbeing\n(Recommendation 120).\n− The Government Response to the Senate Community Affairs References Committee\nReport: Assessment and support services for people with ADHD was tabled on\n12 December 2024, and supports in principle the continued investment in ADHD-\nrelated research, noting the availability of open competitive research programs\nadministered by NHMRC.\n− The Government Response to the Senate Standing Committee on Community\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n- [Page 110]\n4\nOperating environment\nTable 8: NHMRC Audit and Risk Committee, 2024–25\nName Qualifications, knowledge, Attendance/ Annual Role\nskills or experience total remuneration\nmeetings (GST inclusive)\nMr Geoff Knuckey Independent professional 3/3 $6,000 Independent\nFCA accounting experience; Chair\nChartered Accountant and\nGraduate of the Australian\nInstitute of Company\nDirectors (GAICD)\nProfessor Anthony Understanding of entity’s 3/3 $0a Member,\nLawler GAICD operating context, including full year\nhealth care and public policy,\ngovernance and regulation;\nGAICD\nProfessor Eleanor Understanding of entity’s 3/3 $4,590b Member,\nMilligan operating context, including full year\nhealthcare ethics, organisational\nculture and governance; GAICD\nMs Fran Raymond Knowledge of financial and 3/3 $4,590b Member,\nFCA FAICD MBA performance reporting, full year\nincluding accounting and\naudit standards;\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n\n## Corporate Values and Operating Culture\n\n- Overarching values identified from stakeholder responses (column 1) and common subthemes\nBroad theme\nSubthemes\nRespect\nRespect for lived experience\nMutual respect\nRespect for different backgrounds\nRespect for different perspectives\nRespect for skills and knowledge\nRespect for consumer contributions through recognition and remuneration\nEquity\nConsumers treated as equal members of the team\nAddress disparities in research access\nImprove representativeness of research\nEquity of resourcing for consumer organisations\nAddressing/ acknowledging power imbalance between researchers and consumers\nDiversity\nInvolve consumers from a range of backgrounds and experiences\nIntersectionality\nResearch must reflect diversity of communities\nInvolvement of underrepresented/marginalised groups\nCultural safety\nInclusiveness\nListening\nAccessibility/ address barriers to access\nUsing accessible language\n Source: `pages/announcements-index__20.html (https://www.nhmrc.gov.au/research-policy/consumer-and-community-involvement/review-statement-consumer-and-community-involvement-health-and-medical-research/online-engagement-report)`\n- [Page 5]\nPart 4: Operating environment 89\nLegislative framework 90\nGovernance and accountability 91\nCouncil and committees 92\nMinisterial advisory committees 107\nExternal scrutiny 107\nCompliance and assurance 109\nDisability reporting 114\nChild Safety Statement 2024–25 115\nResearch integrity 116\nAccountability 118\nEnvironmental management 122\nPart 5: People management 125\nOrganisational culture 126\nWorkforce planning 127\nManaging and developing employees 127\nTraining and development 128\nDiversity, inclusion and reconciliation 128\nEmployee statistics 130\nStaff movements 132\nWorkplace agreements 132\nWork health and safety 134\nPart 6: Financial performance 137\nFinancial performance summary 138\nAgency resource statement 139\nFinancial statements 140\nPart 7: Appendices 161\nAppendix 1: Public consultations 162\nAppendix 2: Additional information on employees under the Public Service Act 163\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n- The framework compliments Australian Public Service (APS) Values,\nsets clear expectations, and empowers our workforce to model integrity, respect\nand accountability.\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n- [Page 3]\nContents\nAcknowledgment of Country 4\nMessage from the CEO 5\nStatement of preparation 7\nNHMRC’s values 8\nOverview 9\nPurposes 10\nLegislative context 11\nStrategy 12\nOverview 13\nNHMRC Council and Committees 14\nStrategic priorities 16\nHealth priorities 18\nCooperation 20\nConsumers and community groups 21\nIndustry organisations 21\nGovernment relations and other research funders 21\nResearchers and research organisations 23\nOperating context 24\nGovernance and accountability 25\nEnvironment 26\nRisk oversight and management 28\nCapability 33\nActivities 38\nKey activities 40\nPerformance 44\nPerformance measures 46\nAppendix A: List of requirements 50\nNational Health and Medical Research Council | Corporate Plan 2025-26 3\n Source: `corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)`\n- [Page 35]\nAnnual Report of the National Health and Medical Research Council 2015–2016\nTrOPer\neCNAMrOfreP\n2\nTRAP\nINVESTMENT\nGoal 5: Participate in developing national strategies for research infrastructure investment\nTarget 1 Develop policies for national research infrastructure investment that will reduce duplication and work ongoing\nencourage collaboration\nTarget 2 Award eligible independent medical research institutes approximately 20 cents per dollar of the Achieved\ntotal yearly value of grants held\nOutcome 5: NHMRC continues to develop policies and invest in national research infrastructure.\n Source: `annual-reports/2015-16.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf)`\n- [Page 6]\niv Annual Report of the National Health and Medical Research Council 2016–2017 Annual Report of the National Health and Medical Research Council 2016–2017\nstnetnoc\nContents\nAbout the report vii\nPART 1 OVERVIEW VIII\nChief Executive Officer’s review 2\nNHMRC overview 6\nResearch funding expenditure 8\nFunding snapshot 9\nPromoting excellence through NHMRC Awards 10\nTen of the best NHMRC research projects 16\nPART 2 ANNUAL PERFORMANCE STATEMENTS 20\nStatement by the accountable authority 22\nPurposes 23\nPerformance framework 24\nExpenses and resources 25\nResults summary 26\nPurpose 1: Investment 31\nPurpose 2: Translation 52\nPurpose 3: Integrity 70\nCase study: ART Working Committee 77\nPART 3 OPERATING ENVIRONMENT 78\nLegislative framework 80\nCorporate governance 81\nExternal scrutiny 87\nCompliance and assurance 88\nResearch integrity 92\nAccountability 94\n Source: `annual-reports/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf)`\n- [Page 97]\nAnnual Report of the National Health and Medical Research Council 2016–2017 87\ntnemnorivne\ngnitarepo\n3\nTRAP\nExternal scrutiny\nIn addition to its accountability obligations under the NHMRC Act, NHMRC is accountable to\nCommonwealth bodies including the Commonwealth Ombudsman, the Australian Public Service\nCommission, the Office of the Australian Information Commissioner, the Australian Commission for\nLaw Enforcement Integrity, and the Australian National Audit Office.\n Source: `annual-reports/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf)`\n- [Page 181]\n7\nAppendix 4: Abbreviations and acronyms\nN\nNABERS National Australian Built Environment Rating System\nNAIDOC National Aborigines and Islanders Day Observance Committee\nNBCSP National Bowel Cancer Screening Program\nNHMRC Act National Health and Medical Research Council Act 1992\nNHMRC National Health and Medical Research Council\nNSW New South Wales\nNT Northern Territory\nO\nOAIC Office of the Australian Information Commissioner\nOAM Medal of the Order of Australia\nOSM optimal management structure\nP\nPBS Portfolio Budget Statements\nPFAS per-fluoroalkyl and poly-fluoroalkyl substances\nPGPA Act Public Governance, Performance and Accountability Act 2013\nPGPA Rule Public Governance, Performance and Accountability Rule 2014\nPHCR Act Prohibition of Human Cloning for Reproduction Act 2002\nPHHSC Public Health and Health Systems Committee\nPhD Doctor of Philosophy\nPRM peer review mentor\n Source: `annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)`\n\n## Global Ideas and Case Study Inputs\n\n_No global-intelligence source text found yet. Run `CLAUDE/global-ideas-scraper.py ` to populate case-study sources._\n\n## Source Artifacts Used\n\n- `corporate-plans/2016-17.pdf` - corporate-plans - https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf\n- `corporate-plans/2017-18.pdf` - corporate-plans - https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/4ba2e828-a6a9-4c84-beab-a45c39967b6e/upload_pdf/17293_nhmrc_corporate_plan_2017-18-web.pdf;fileType=application%2Fpdf\n- `corporate-plans/2018-19.pdf` - corporate-plans - https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/77446457-0aed-405b-b234-73321c169df2/upload_pdf/corporate-plan-2018-2019.pdf;fileType=application%2Fpdf\n- `corporate-plans/2024-25.pdf` - corporate-plans - https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf\n- `corporate-plans/2025-26.pdf` - corporate-plans - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf\n- `annual-reports/2014-15.pdf` - annual-reports - https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf\n- `annual-reports/2015-16.pdf` - annual-reports - https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf\n- `annual-reports/2016-17.pdf` - annual-reports - https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf\n- `annual-reports/2023-24.pdf` - annual-reports - https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf\n- `annual-reports/2024-25.pdf` - annual-reports - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf\n- `strategies/NHMRC_Gender_Equity_Strategy_FA.pdf` - strategies - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/NHMRC_Gender_Equity_Strategy_FA.pdf\n- `strategies/national_consumer_framework_web_504af020f2184.pdf` - strategies - https://www.canceraustralia.gov.au/sites/default/files/migrated-files/publications/national_consumer_framework_web_504af020f2184.pdf\n- `reviews/final-report-national-scientific-committees.pdf` - reviews - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/final-report-national-scientific-committees.pdf\n- `pages/about.html` - pages - https://www.nhmrc.gov.au/about-us\n- `pages/announcements-index.html` - pages - https://www.nhmrc.gov.au/research-policy/consumer-and-community-involvement/review-statement-consumer-and-community-involvement-health-and-medical-research/completed-consultation-activities\n- `pages/announcements-index__16.html` - pages - https://www.nhmrc.gov.au/research-policy/consumer-and-community-involvement/review-statement-consumer-and-community-involvement-health-and-medical-research/completed-consultation-activities\n- `pages/announcements-index__17.html` - pages - https://www.nhmrc.gov.au/research-policy/consumer-and-community-involvement/review-statement-consumer-and-community-involvement-health-and-medical-research\n- `pages/announcements-index__18.html` - pages - https://www.nhmrc.gov.au/research-policy/consumer-and-community-involvement/review-statement-consumer-and-community-involvement-health-and-medical-research/videos-and-case-studies\n- `pages/announcements-index__19.html` - pages - https://www.nhmrc.gov.au/research-policy/consumer-and-community-involvement/review-statement-consumer-and-community-involvement-health-and-medical-research/timeline\n- `pages/announcements-index__20.html` - pages - https://www.nhmrc.gov.au/research-policy/consumer-and-community-involvement/review-statement-consumer-and-community-involvement-health-and-medical-research/online-engagement-report\n- `pages/announcements-index__21.html` - pages - https://www.nhmrc.gov.au/about-us/publications/review-2016-statement-consumer-and-community-involvement-health-and-medical-research-2025-consultation-report\n- `pages/announcements-index__22.html` - pages - https://www.nhmrc.gov.au/node/8162\n- `pages/announcements-index__23.html` - pages - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Consumer-statement/2025%20survey%20response%20-%20Canberra%20Health%20Service.pdf\n- `pages/announcements-index__24.html` - pages - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Consumer-statement/2025%20survey%20response%20-%20Research%20Australia.pdf\n- `pages/announcements-index__25.html` - pages - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Consumer-statement/2025%20survey%20response%20-%20National%20Rural%20Health.pdf\n- `pages/announcements-index__26.html` - pages - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Consumer-statement/2025%20survey%20response%20-%20Health%20Consumers%20NSW.pdf\n- `pages/announcements-index__27.html` - pages - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Consumer-statement/2025%20survey%20response%20-%20Health%20Consumers%20NSW-2.pdf\n- `pages/announcements-index__28.html` - pages - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Consumer-statement/2025%20survey%20response%20-%20Deakin%20University.pdf\n- `pages/announcements-index__29.html` - pages - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Consumer-statement/2025%20survey%20response%20-%20Council%20of%20Deans%20of%20Nursing%20and%20midwifery.pdf\n- `pages/annual-reports-index.html` - pages - https://www.nhmrc.gov.au/about-us/corporate-plans-and-annual-reports\n- `pages/annual-reports-index__00.html` - pages - https://www.nhmrc.gov.au/about-us/publications/annual-report-2024-25\n- `pages/annual-reports-index__01.html` - pages - https://www.nhmrc.gov.au/about-us/publications/annual-report-2023-24\n- `pages/corporate-plans-index.html` - pages - https://www.nhmrc.gov.au/about-us/corporate-plans-and-annual-reports\n- `pages/corporate-plans-index__02.html` - pages - https://www.nhmrc.gov.au/about-us/publications/nhmrc-corporate-plan-2025-26\n- `pages/corporate-plans-index__03.html` - pages - https://www.nhmrc.gov.au/about-us/publications/nhmrc-corporate-plan-2024-25\n- `pages/homepage.html` - pages - https://www.nhmrc.gov.au/about-us/leadership-and-governance/council\n- `pages/leadership.html` - pages - https://www.nhmrc.gov.au/about-us/leadership-and-governance/council\n- `pages/ministers.html` - pages - https://www.nhmrc.gov.au/funding/manage-your-funding/nhmrc-funding/administering-institutions\n- `pages/news-latest.html` - pages - https://www.nhmrc.gov.au/about-us/news-centre\n- `pages/publications-index.html` - pages - https://www.nhmrc.gov.au/about-us/publications\n- `pages/reforms-index.html` - pages - https://www.nhmrc.gov.au/research-policy/clinical-trial-reform\n- `pages/reforms-index__14.html` - pages - https://www.nhmrc.gov.au/research-policy/clinical-trial-reform\n- `pages/reforms-index__15.html` - pages - https://www.nhmrc.gov.au/file/14281/download?token=yf_EGIEL\n- `pages/strategies-index.html` - pages - https://www.nhmrc.gov.au/research-policy/gender-equity/nhmrc-gender-equity-strategy\n- `pages/strategies-index__04.html` - pages - https://www.nhmrc.gov.au/research-policy/gender-equity/nhmrc-gender-equity-strategy\n- `pages/strategies-index__05.html` - pages - https://www.nhmrc.gov.au/funding/data-research/outcomes-funding-rounds\n- `pages/strategies-index__06.html` - pages - https://www.nhmrc.gov.au/funding/outcomes-and-data-research\n- `pages/strategies-index__07.html` - pages - https://www.nhmrc.gov.au/funding/outcomes-and-data-research/research-funding-statistics-and-data\n- `pages/strategies-index__08.html` - pages - https://www.nhmrc.gov.au/sites/default/files/documents/attachments/NHMRC_Gender_Equity_Strategy_FA.pdf\n- `pages/strategies-index__09.html` - pages - https://www.nhmrc.gov.au/file/24491/download?token=VXDYnUP_\n- `pages/strategies-index__10.html` - pages - https://www.nhmrc.gov.au/funding/international-collaborative-funding/international-engagement-strategy-and-activities\n- `pages/strategies-index__11.html` - pages - https://www.nhmrc.gov.au/funding/data-research/outcomes\n- `pages/strategies-index__12.html` - pages - https://www.nhmrc.gov.au/funding/outcomes-and-data-research/data-dictionary-and-data-glossary\n- `pages/strategies-index__13.html` - pages - https://www.nhmrc.gov.au/research-policy/research-priorities/framework-identifying-and-prioritising-targeted-calls-research\n- `pages/structure.html` - pages - https://www.nhmrc.gov.au/funding/manage-your-funding/mrff-funding/mrff-eligible-organisations\n- `other-pdfs/council-minutes-july-2017.pdf` - other-pdfs - https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-july-2017.pdf\n- `other-pdfs/council-minutes-october-2017.pdf` - other-pdfs - https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-october-2017.pdf\n- `other-pdfs/council-minutes-june-2018.pdf` - other-pdfs - https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-june-2018.pdf\n- `other-pdfs/council-minutes-march-2018.pdf` - other-pdfs - https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-march-2018.pdf\n- `other-pdfs/council-minutes-november-2018.pdf` - other-pdfs - https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-november-2018.pdf\n\n## Gaps To Fix\n\n- No global comparison/case-study sources found.", "legislation_md": "# National Health and Medical Research Council - Commissioner of Complaints - Acts and Legislation Discovery\n\n**Generated at**: 2026-05-09T21:11:37.486015+00:00\n**Entity ID**: B-001935\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n\n> This is an evidence-based discovery list from scraped department material. A mention does not always mean the department administers the legislation; high-confidence and official register links should be reviewed.\n\n## Summary\n\n- Source files scanned: 60\n- Unique legislation references found: 72\n\n| Type | Count |\n|---|---:|\n| Act | 68 |\n| Code | 3 |\n| Determination | 1 |\n\n## Legislation References\n\n### Public Governance, Performance and Accountability Act 2013\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 54\n**Register search**: https://www.legislation.gov.au/search?query=Public+Governance%2C+Performance+and+Accountability+Act+2013\n\n**Sources**:\n- `pages/annual-reports-index.html`\n- `pages/corporate-plans-index.html`\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n- `corporate-plans/2016-17.pages.jsonl`\n- `corporate-plans/2017-18.pages.jsonl`\n- `corporate-plans/2018-19.pages.jsonl`\n\n**Evidence contexts**:\n- Corporate plans and annual reports | NHMRC\n\nWe publish corporate plans and annual reports in line with the\nPublic Governance, Performance and Accountability Act 2013\n. Our corporate plan sets our direction and objectives. Our annual report shows how we have performed in achieving our objectives. Find a list below of our corporate documents dating back to 1938.\nCorporate plan\nOur corporate plan presents our national strate\n Source: `pages/annual-reports-index.html`\n- 023–24\n2022–23\n2022–23\n2021–22\n2021–22\n2020–21\n2020–21\n2019–20\n2019–20\n2018–19\n2018–19\n2017–18\n2017–18\n2010 to 2016\nCorporate Plans and Strategic Plans\na\nAnnual Reports\na\nNHMRC published its first 'Corporate Plan' in 2015, in line with the requirements of the\nPublic Governance, Performance and Accountability Act 2013\nand\nNational Health and Medical Research Council Act 1992\n(NHMRC Act). Before 2015, NHMRC published its national strategy for health and medical research, major national health issues, as well as its key actions, in a 'Strategic Plan' for the triennium. This\n Source: `pages/annual-reports-index.html`\n- Corporate plans and annual reports | NHMRC\n\nWe publish corporate plans and annual reports in line with the\nPublic Governance, Performance and Accountability Act 2013\n. Our corporate plan sets our direction and objectives. Our annual report shows how we have performed in achieving our objectives. Find a list below of our corporate documents dating back to 1938.\nCorporate plan\nOur corporate plan presents our national strate\n Source: `pages/corporate-plans-index.html`\n- 023–24\n2022–23\n2022–23\n2021–22\n2021–22\n2020–21\n2020–21\n2019–20\n2019–20\n2018–19\n2018–19\n2017–18\n2017–18\n2010 to 2016\nCorporate Plans and Strategic Plans\na\nAnnual Reports\na\nNHMRC published its first 'Corporate Plan' in 2015, in line with the requirements of the\nPublic Governance, Performance and Accountability Act 2013\nand\nNational Health and Medical Research Council Act 1992\n(NHMRC Act). Before 2015, NHMRC published its national strategy for health and medical research, major national health issues, as well as its key actions, in a 'Strategic Plan' for the triennium. This\n Source: `pages/corporate-plans-index.html`\n- he Prohibition of Human Cloning for Reproduction Act 2002\nand the Research Involving Human Embryos Act 2002.\nThe report has been prepared in accordance with section 83 of the National Health and\nMedical Research Council Act 1992 (NHMRC Act), section 46 of the Public Governance,\nPerformance and Accountability Act 2013 and the Requirements for Annual Reports\napproved by the Joint Committee of Public Accounts and Audit under subsections 63(2)\nand 70(2) of the Public Service Act 1999.\nThe report includes the matters set out in section 83 of the NHMRC Act, and also details\ninf\n Source: `annual-reports/2014-15.pages.jsonl`\n\n### National Health and Medical Research Council Act 1992\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 47\n**Register search**: https://www.legislation.gov.au/search?query=National+Health+and+Medical+Research+Council+Act+1992\n\n**Sources**:\n- `pages/annual-reports-index.html`\n- `pages/corporate-plans-index.html`\n- `pages/homepage.html`\n- `pages/leadership.html`\n- `pages/strategies-index__12.html`\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- 2019–20\n2018–19\n2018–19\n2017–18\n2017–18\n2010 to 2016\nCorporate Plans and Strategic Plans\na\nAnnual Reports\na\nNHMRC published its first 'Corporate Plan' in 2015, in line with the requirements of the\nPublic Governance, Performance and Accountability Act 2013\nand\nNational Health and Medical Research Council Act 1992\n(NHMRC Act). Before 2015, NHMRC published its national strategy for health and medical research, major national health issues, as well as its key actions, in a 'Strategic Plan' for the triennium. This was in line with the then requirements of the NHMRC Act.\n2\n Source: `pages/annual-reports-index.html`\n- Plans\nb\nAnnual Reports\nb\nBefore 2015, NHMRC published its national strategy for health and medical research, major national health issues, as well as its key actions, in a ‘Strategic Plan’ for the triennium. This was in line with the then requirements of the\nNational Health and Medical Research Council Act 1992\n.\n2007-2009\n2009–10\n2008–09\n2007–08\n2003–2006\n2006-07\n2005\n2004\n2003\n2000-2003\n2002\n2001\n2000\n1990s\nNHMRC Strategic Plans\nc\nNHMRC Annual Reports\nCommonwealth Department responsible for Health Annual Reports\nd\nNHMRC Reports upon work under the Medical Research\n Source: `pages/annual-reports-index.html`\n- esearch Endowment Act\ne\nc\nBefore 2015, NHMRC published its national strategy for health and medical research, major national health issues, as well as its key actions, in a 'Strategic Plan' for the triennium. This was in line with the then requirements of the\nNational Health and Medical Research Council Act 1992\n(NHMRC Act). NHMRC published its first Strategic Plan in 1993, the same year it became a Statutory Authority under the NHMRC Act.\nd\nBefore 1993, NHMRC was part of the Commonwealth Department of Health and reported accordingly.\ne\nThese documents report on the\n Source: `pages/annual-reports-index.html`\n- 2019–20\n2018–19\n2018–19\n2017–18\n2017–18\n2010 to 2016\nCorporate Plans and Strategic Plans\na\nAnnual Reports\na\nNHMRC published its first 'Corporate Plan' in 2015, in line with the requirements of the\nPublic Governance, Performance and Accountability Act 2013\nand\nNational Health and Medical Research Council Act 1992\n(NHMRC Act). Before 2015, NHMRC published its national strategy for health and medical research, major national health issues, as well as its key actions, in a 'Strategic Plan' for the triennium. This was in line with the then requirements of the NHMRC Act.\n2\n Source: `pages/corporate-plans-index.html`\n- Plans\nb\nAnnual Reports\nb\nBefore 2015, NHMRC published its national strategy for health and medical research, major national health issues, as well as its key actions, in a ‘Strategic Plan’ for the triennium. This was in line with the then requirements of the\nNational Health and Medical Research Council Act 1992\n.\n2007-2009\n2009–10\n2008–09\n2007–08\n2003–2006\n2006-07\n2005\n2004\n2003\n2000-2003\n2002\n2001\n2000\n1990s\nNHMRC Strategic Plans\nc\nNHMRC Annual Reports\nCommonwealth Department responsible for Health Annual Reports\nd\nNHMRC Reports upon work under the Medical Research\n Source: `pages/corporate-plans-index.html`\n\n### Research Involving Human Embryos Act 2002\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 47\n**Register search**: https://www.legislation.gov.au/search?query=Research+Involving+Human+Embryos+Act+2002\n\n**Sources**:\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n- `corporate-plans/2016-17.pages.jsonl`\n- `corporate-plans/2017-18.pages.jsonl`\n- `corporate-plans/2024-25.pages.jsonl`\n- `corporate-plans/2025-26.pages.jsonl`\n- `other-pdfs/council-minutes-july-2017.pages.jsonl`\n\n**Evidence contexts**:\n- in health and medical research, developing evidence based health advice,\nproviding advice on ethical practice in health care and the conduct of medical research and\nperforming functions under the Prohibition of Human Cloning for Reproduction Act 2002\nand the Research Involving Human Embryos Act 2002.\nThe report has been prepared in accordance with section 83 of the National Health and\nMedical Research Council Act 1992 (NHMRC Act), section 46 of the Public Governance,\nPerformance and Accountability Act 2013 and the Requirements for Annual Reports\napproved\n Source: `annual-reports/2014-15.pages.jsonl`\n- and territories, health bodies, health industries and community and\nconsumers groups.\nNHMRC is an independent statutory agency operating under the NHMRC Act. It has statutory obligations\nunder the Prohibition of Human Cloning for Reproduction Act 2002 and the Research Involving Human\nEmbryos Act 2002.\nNHMRC is a non-corporate Commonwealth entity under the Public Governance, Performance and\nAccountability Act 2013 and is subject to the Public Service Act 1999.\nFigure 1 Structure of NHMRC\nMinister for Health\nCouncil Chief Executive Officer\nStaff of the Offi\n Source: `annual-reports/2014-15.pages.jsonl`\n- or the 2012–15 triennium, NHMRC comprised the following six Principal Committees:\n• Australian Health Ethics Committee (required under the NHMRC Act)\n• Research Committee (required under the NHMRC Act)\n• Embryo Research Licensing Committee (required under the Research Involving Human Embryos Act\n2002)\n• Human Genetics Advisory Committee\n• Health Care Committee\n• Prevention and Community Health Committee.\nThe terms of reference for the Principal Committees were gazetted by the then Minister for Health on 28\nMarch 2012. The Chair of each Principal Committee\n Source: `annual-reports/2014-15.pages.jsonl`\n- ncluding the Research Ethics Committee of the Australian\nBone Marrow Registry (ABMDR). In 2005/6 Associate Professor Kerridge was a member\nof the Legislation Review Committee (Lockhart Committee) that reviewed the Prohibition of Human Cloning\nAct 2002 and the Research Involving Human Embryos Act 2002. During the 2013-15 NHMRC triennium\nAssociate Professor Kerridge was a member of NHMRC’s Australian Health Ethics Committee (2012 - 2015),\nAssisted Reproductive Technology Review Committee (2013 - 2015), and part of the Clinical Ethics Capacity\nBuilding Worki\n Source: `annual-reports/2014-15.pages.jsonl`\n- 30 June 2015 the NHMRC has no contingent assets.\nAs at 30 June 2015 the NHMRC has the following contingent liabilities:\nThe NHMRC has in place a deed of standing offer with a panel of investigators to provide investigation\nservices if serious breaches of the Research Involving Human Embryos Act 2002 or the Prohibition of\nHuman Cloning for Reproduction Act 2002 are identified.\nThe consequence of the contingency being triggered is estimated to be a cost of approximately $150,000.\nUnquantifiable Contingencies\nAt 30 June 2015, the NHMRC had no unquantifiable\n Source: `annual-reports/2014-15.pages.jsonl`\n\n### Prohibition of Human Cloning for Reproduction Act 2002\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 39\n**Register search**: https://www.legislation.gov.au/search?query=Prohibition+of+Human+Cloning+for+Reproduction+Act+2002\n\n**Sources**:\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n- `corporate-plans/2017-18.pages.jsonl`\n- `corporate-plans/2024-25.pages.jsonl`\n- `corporate-plans/2025-26.pages.jsonl`\n- `other-pdfs/council-minutes-july-2017.pages.jsonl`\n- `other-pdfs/council-minutes-june-2018.pages.jsonl`\n\n**Evidence contexts**:\n- d to deliver on the strategic directions of managing\ninvestment in health and medical research, developing evidence based health advice,\nproviding advice on ethical practice in health care and the conduct of medical research and\nperforming functions under the Prohibition of Human Cloning for Reproduction Act 2002\nand the Research Involving Human Embryos Act 2002.\nThe report has been prepared in accordance with section 83 of the National Health and\nMedical Research Council Act 1992 (NHMRC Act), section 46 of the Public Governance,\nPerformance and Accountability Act 201\n Source: `annual-reports/2014-15.pages.jsonl`\n- hics in health care and research\n• work with partners – states and territories, health bodies, health industries and community and\nconsumers groups.\nNHMRC is an independent statutory agency operating under the NHMRC Act. It has statutory obligations\nunder the Prohibition of Human Cloning for Reproduction Act 2002 and the Research Involving Human\nEmbryos Act 2002.\nNHMRC is a non-corporate Commonwealth entity under the Public Governance, Performance and\nAccountability Act 2013 and is subject to the Public Service Act 1999.\nFigure 1 Structure of NHMRC\nMinister for Health\n Source: `annual-reports/2014-15.pages.jsonl`\n- cies and the Consumers Health Forum.\n71\nAnnual Report of the National Health and Medical Research Council 2014–2015\n\n[page 80]\nPART 2 REPORT ON ACTIVITIES\nEMBRYO RESEARCH LICENSING COMMITTEE\nThe NHMRC Embryo Research Licensing Committee (ERLC) administers the Prohibition of Human Cloning\nfor Reproduction Act 2002 (PHCR Act) and the Research Involving Human Embryos Act 2002 (RIHE\nAct). These Acts regulate research activities that use human embryos created by assisted reproductive\ntechnology or other means. There are strong penalties for noncompliance. The Acts also pro\n Source: `annual-reports/2014-15.pages.jsonl`\n- As at 30 June 2015 the NHMRC has the following contingent liabilities:\nThe NHMRC has in place a deed of standing offer with a panel of investigators to provide investigation\nservices if serious breaches of the Research Involving Human Embryos Act 2002 or the Prohibition of\nHuman Cloning for Reproduction Act 2002 are identified.\nThe consequence of the contingency being triggered is estimated to be a cost of approximately $150,000.\nUnquantifiable Contingencies\nAt 30 June 2015, the NHMRC had no unquantifiable contingencies.\nSignificant Remote Contingencies\nThe NHMRC has\n Source: `annual-reports/2014-15.pages.jsonl`\n- 15 Annual Report of the National Health and Medical Research Council 2014–2015\n\n[page 175]\nAPPENDIXES PART 5\nAPPENDIX 4: EMBRYO RESEARCH LICENSING\nCOMMITTEE\nThe Embryo Research Licensing Committee oversees the Research Involving Human Embryos Act 2002\nand the Prohibition of Human Cloning for Reproduction Act 2002. The legislation prohibits certain practices,\nincluding human cloning for reproduction. It regulates use of excess human embryos created through\nassisted reproductive technology (ART), the creation of embryos by other means and use of such embryos\nfor researc\n Source: `annual-reports/2014-15.pages.jsonl`\n\n### Public Service Act 1999\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 21\n**Register search**: https://www.legislation.gov.au/search?query=Public+Service+Act+1999\n\n**Sources**:\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- l Research Council Act 1992 (NHMRC Act), section 46 of the Public Governance,\nPerformance and Accountability Act 2013 and the Requirements for Annual Reports\napproved by the Joint Committee of Public Accounts and Audit under subsections 63(2)\nand 70(2) of the Public Service Act 1999.\nThe report includes the matters set out in section 83 of the NHMRC Act, and also details\ninformation required by other applicable legislation, including the Public Governance,\nPerformance and Accountability Act 2013, the Freedom of Information Act 1982, the\n Source: `annual-reports/2014-15.pages.jsonl`\n- Annual Report was prepared in accordance\nwith section 83 of the National Health and Medical Research Council Act 1992 and the Requirements for\nAnnual Reports approved by the Joint Committee of Public Accounts and Audit under subsections 63(2) and\n70(2) of the Public Service Act 1999.\nIt is a record of NHMRC’s activities during 2014–15 and the performance and financial information presented\nin the 2014–15 NHMRC Portfolio (Agency) Budget Statement and 2014–15 NHMRC Portfolio Additional\nEstimates Statement.\nThe report is structured as follo\n Source: `annual-reports/2014-15.pages.jsonl`\n- gations\nunder the Prohibition of Human Cloning for Reproduction Act 2002 and the Research Involving Human\nEmbryos Act 2002.\nNHMRC is a non-corporate Commonwealth entity under the Public Governance, Performance and\nAccountability Act 2013 and is subject to the Public Service Act 1999.\nFigure 1 Structure of NHMRC\nMinister for Health\nCouncil Chief Executive Officer\nStaff of the Office of the Embryo Research\nResearch Committee\nNHMRC Licensing Committee\nAustralian Health Ethics\nCommittee\nHealth Care Committee\nPrevention and Community\nHealth C\n Source: `annual-reports/2014-15.pages.jsonl`\n- National Health and Medical Research Council 2014–2015 Annual Report of the National Health and Medical Research Council 2014–2015\n\n[page 99]\nCORPORATE REPORTING PART 3\nOTHER EMPLOYMENT INSTRUMENTS\nThere were no determinations made under section 24(1) of the Public Service Act 1999 between 1 July 2014\nand 30 June 2015.\nPERFORMANCE PAY\nThe Performance Partnerships Program operates with pay point progression available to employees\nwho achieve an ‘effective’ rating during the performance cycle, which runs from July to June each year.\nPerfo\n Source: `annual-reports/2014-15.pages.jsonl`\n- in health care and the conduct of medical research, and performing functions\nunder the Prohibition of Human Cloning for Reproduction Act 2002 and the Research\nInvolving Human Embryos Act 2002.\nThe report has been prepared in accordance with section 70 of the Public Service Act\n1999, section 83 of the National Health and Medical Research Council Act 1992 (NHMRC\nAct), section 46 of the Public Governance, Performance and Accountability Act 2013 and\nthe Requirements for Annual Reports approved by the Joint Committee of Public Accounts\nand A\n Source: `annual-reports/2015-16.pages.jsonl`\n\n### Medical Research Endowment Act 1937\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 16\n**Register search**: https://www.legislation.gov.au/search?query=Medical+Research+Endowment+Act+1937\n\n**Sources**:\n- `pages/annual-reports-index.html`\n- `pages/corporate-plans-index.html`\n\n**Evidence contexts**:\n- record of our activities for the reporting period.\nFind our most recent\nannual reports on the Publications page\n.\nCorporate documents from 1930s to today\nWe have corporate documents dating back to 1938, when we first presented a report to Parliament under the\nMedical Research Endowment Act 1937\n.\nBelow is a list of corporate documents from 1938 to today. We have included links to the published documents where available online.\n2017 to current\nCorporate Plans\nAnnual Reports\n2025–26\nAvailable in late 2026\n2024–25\n2024–25\n2023–24\n2023–24\n2022–23\n2022–2\n Source: `pages/annual-reports-index.html`\n- its first Strategic Plan in 1993, the same year it became a Statutory Authority under the NHMRC Act.\nd\nBefore 1993, NHMRC was part of the Commonwealth Department of Health and reported accordingly.\ne\nThese documents report on the annual administration of the\nMedical Research Endowment Act 1937\n, including details on grants paid for medical research from the Medical Research Endowment Fund. This report ceased after 1992, as the Medical Research Endowment Act was repealed by the NHMRC Act.\n1997–2000\n1999\n1998\n1997\n1994–1996\n1996\n1995\n1994\n1993–1994\n1\n Source: `pages/annual-reports-index.html`\n- nsible for Health Annual Reports\nd\nNHMRC Reports upon work under the Medical Research Endowment Act\ne\nd\nBefore 1993, NHMRC was part of the Commonwealth Department of Health and reported accordingly.\ne\nThese documents report on the annual administration of the\nMedical Research Endowment Act 1937\n, including details on grants paid for medical research from the Medical Research Endowment Fund. This report ceased after 1992, as the Medical Research Endowment Act was repealed by the NHMRC Act.\n1989-90\n1989\n1988-89\n1988\n1987-88\n1987\n1986-87\n1986\n1985-86\n1\n Source: `pages/annual-reports-index.html`\n- nsible for Health Annual Reports\nd\nNHMRC Reports upon work under the Medical Research Endowment Act\ne\nd\nBefore 1993, NHMRC was part of the Commonwealth Department of Health and reported accordingly.\ne\nThese documents report on the annual administration of the\nMedical Research Endowment Act 1937\n, including details on grants paid for medical research from the Medical Research Endowment Fund. This report ceased after 1992, as the Medical Research Endowment Act was repealed by the NHMRC Act.\n1979-80\n1979\n1978-79\n1978\n1977-78\n1977\n1976-77\n1976\n1975-76\n1\n Source: `pages/annual-reports-index.html`\n- nsible for Health Annual Reports\nd\nNHMRC Reports upon work under the Medical Research Endowment Act\ne\nd\nBefore 1993, NHMRC was part of the Commonwealth Department of Health and reported accordingly.\ne\nThese documents report on the annual administration of the\nMedical Research Endowment Act 1937\n, including details on grants paid for medical research from the Medical Research Endowment Fund. This report ceased after 1992, as the Medical Research Endowment Act was repealed by the NHMRC Act.\n1969-70\n1969\n1968-69\n1968\n1967-68\n1967\n1966-67\n1966\n1965-66\n1\n Source: `pages/annual-reports-index.html`\n\n### Medical Research Future Fund Act 2015\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 14\n**Register search**: https://www.legislation.gov.au/search?query=Medical+Research+Future+Fund+Act+2015\n\n**Sources**:\n- `pages/structure.html`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n- `corporate-plans/2017-18.pages.jsonl`\n- `corporate-plans/2024-25.pages.jsonl`\n- `corporate-plans/2025-26.pages.jsonl`\n\n**Evidence contexts**:\n- come an MRFF EO is managed by the grant hub administering the relevant MRFF funding – that is, NHMRC or the Business Grants Hub (BGH). This page outlines the process for obtaining EO status to apply for MRFF funding administered by NHMRC.\nThe objective of the\nMedical Research Future Fund Act 2015\nis to improve the health and wellbeing of Australians. The role of an MRFF EO is to support this objective by undertaking medical research and medical innovation activities in accordance with the terms and conditions set out in any MRFF Funding Agreement to w\n Source: `pages/structure.html`\n- penditure on public health research and training, and\nmedical research and training.\nNHMRC also administers, and has statutory obligations under, the Prohibition of Human Cloning for\nReproduction Act 2002, the Research Involving Human Embryos Act 2002 and the Medical Research Future\nFund Act 2015.\n\n[page 91]\nAnnual Report of the National Health and Medical Research Council 2016–2017 81\ntnemnorivne\ngnitarepo\n3\nTRAP\nCorporate\ngovernance\nNHMRC’s robust corporate governance and compliance framework applies rigour and discipline to the way\nin which NHMRC d\n Source: `annual-reports/2016-17.pages.jsonl`\n- f ethics and integrity in health and medical research.\nThroughout 2023–24, NHMRC has also continued to perform its functions under the NHMRC\nAct, the Prohibition of Human Cloning for Reproduction Act 2002, the Research Involving\nHuman Embryos Act 2002 and the Medical Research Future Fund Act 2015.\nThis report includes the annual report of the NHMRC Commissioner of Complaints, as required\nunder section 68 of the NHMRC Act. It also includes a report on the activities of the Australian\nResearch Integrity Committee.\nAs required under section 10 of the Pub\n Source: `annual-reports/2023-24.pages.jsonl`\n- nd medical research and training.\nWe also administer and have statutory obligations under the Research Involving Human\nEmbryos Act 2002 and the Prohibition of Human Cloning for Reproduction Act 2002.\nIn addition, we exercise some statutory functions under the Medical Research Future\nFund Act 2015.\nWe develop evidence-based health advice using rigorous methodologies and translate\nresearch findings into high-quality evidence-based practice guidelines for the Australian\ncommunity, health professionals and governments. We provide advice on ethical practic\n Source: `annual-reports/2023-24.pages.jsonl`\n- ing, and medical research and training.\nNHMRC also administers the Prohibition of Human Cloning for Reproduction Act\n2002 (PHCR Act) and the Research Involving Human Embryos Act 2002 (RIHE Act).\nAdditionally, NHMRC exercises some statutory functions under the Medical Research\nFuture Fund Act 2015.\nGovernance\nNHMRC operates within a strong governance framework that supports effective\nperformance, integrity, efficiency and compliance with our legislated responsibilities\nunder the NHMRC Act and the PGPA Act, as well as other relevant legislation.\nNHMRC’s\n Source: `annual-reports/2023-24.pages.jsonl`\n\n### Administer the Research Involving Human Embryos Act 2002\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 11\n**Register search**: https://www.legislation.gov.au/search?query=Administer+the+Research+Involving+Human+Embryos+Act+2002\n\n**Sources**:\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n- `corporate-plans/2017-18.pages.jsonl`\n- `corporate-plans/2018-19.pages.jsonl`\n- `corporate-plans/2024-25.pages.jsonl`\n- `corporate-plans/2025-26.pages.jsonl`\n\n**Evidence contexts**:\n- l and Torres Strait Islander Research work ongoing\nEthics Guidelines\nOutcome 3: S ignificant progress has been achieved with the review of research ethics standards\nand guidelines, many of which are associated with highly sensitive and complex issues.\nGoal 4: Administer the Research Involving Human Embryos Act 2002 and the Prohibition of Human\nCloning for Reproduction Act 2002\nTarget 1 Stakeholders demonstrate continued understanding of regulatory requirements work ongoing\nTarget 2 implement new processes to decrease the burden of red tape on businesses work ongoing\nOut\n Source: `annual-reports/2015-16.pages.jsonl`\n- by\nthe sectors.\n82\n\n[page 91]\nAnnual Report of the National Health and Medical Research Council 2015–2016\nTrOPer\neCNAMrOfreP\n2\nTRAP\nGOAL 4: ADMINISTER THE RESEARCH INVOLVING HUMAN EMBRYOS ACT 2002\nAND THE PROHIBITION OF HUMAN CLONING FOR REPRODUCTION ACT 2002\nAdminister the Research Involving Human Embryos Act 2002 and the Activity 3.4 NHMRC\nProhibition of Human Cloning for Reproduction Act 2002. Corporate Plan\nNHMRC will continue to administer the Research Involving Human Portfolio Budget\nEmbryos Act 2002 (RIHE Act) and the Prohibition of Human Cloning for Statement—\nR\n Source: `annual-reports/2015-16.pages.jsonl`\n- protocols and documents without requiring prior approval\nfrom the committee. This will reduce the time between identifying and implementing required changes.\nThe committee will monitor the effect of these processes and make amendments as required.\nOutcome 4: Administer the Research Involving Human Embryos Act 2002 and the\nProhibition of Human Cloning for Reproduction Act 2002\nDuring 2015–16 the Embryo Research Licensing Committee has fulfilled its functions, and through NHMRC,\ncontinued to administer the legislation. Stakeholders indicated that they are satisfied with\n Source: `annual-reports/2015-16.pages.jsonl`\n- vision of research ethics guidelines Achieved\nfor research involving Aboriginal and Torres Strait Islander peoples\nTarget 5 Finalise and release the Principles and guidelines for the care and use of non- Achieved\nhuman primates for scientific purposes\nGoal 4: Administer the Research Involving Human Embryos Act 2002 and the Prohibition of Human\nCloning for Reproduction Act 2002\nTarget 1 Stakeholders demonstrate a continued understanding of regulatory Work ongoing\nrequirements\nTarget 2 Implement processes to decrease the burden of red tape on businesses Work ongoing\nTarge\n Source: `annual-reports/2016-17.pages.jsonl`\n- ttee, with advice from an expert NHMRC working committee. The review culminated\nin the finalisation of the Principles and guidelines for the care and use of non-human primates for scientific\npurposes, which was released on 20 September 2016.\nIntegrity goal 4: Administer the Research Involving Human Embryos Act 2002 and the Prohibition of\nHuman Cloning for Reproduction Act 2002\nActivity 3.4 Corporate plan\np. 35\nAdminister the Research Involving Human Embryos Act 2002 and the Prohibition of\nHuman Cloning for Reproduction Act 2002\nProgram objective E Portfolio budget\nstate\n Source: `annual-reports/2016-17.pages.jsonl`\n\n### RIHE Act) and the Prohibition of Human Cloning for Reproduction Act 2002\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 9\n**Register search**: https://www.legislation.gov.au/search?query=RIHE+Act%29+and+the+Prohibition+of+Human+Cloning+for+Reproduction+Act+2002\n\n**Sources**:\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n- `corporate-plans/2016-17.pages.jsonl`\n- `corporate-plans/2017-18.pages.jsonl`\n- `corporate-plans/2024-25.pages.jsonl`\n- `corporate-plans/2025-26.pages.jsonl`\n\n**Evidence contexts**:\n- e Prohibition of\nHuman Cloning for Reproduction Act 2002\nProgram objective E Portfolio budget\nstatements\nPromoting the highest ethical standards in health and medical research\np. 396\nNHMRC continues to administer the Research Involving Human Embryos Act 2002\n(RIHE Act) and the Prohibition of Human Cloning for Reproduction Act 2002 (PHCR\nAct), which prohibit certain practices, including human cloning for reproduction, and\nrestrict other practices relating to reproductive technology and research.\nTarget 1: Stakeholders demonstrate a continued understanding of regulatory requirements\nCorp\n Source: `annual-reports/2016-17.pages.jsonl`\n- compliance with NHMRC’s policies and\nrequirements\n• respond to an evaluation of the Australian Research Integrity Committee\n• promote best practice in research governance and ethics review processes\n• administer the Research Involving Human Embryos Act 2002 (RIHE Act) and\nthe Prohibition of Human Cloning for Reproduction Act 2002 (PCHR Act), as\namended by the Mitochondrial Donation Law reform (Maeve’s Law) Act 2022,\nthrough the work of the Embryo Research Licensing Committee.\nNational Health and Medical Research Council 51\n\n[page 66]\nPart 3: Annual performance statements\nAnalysis of p\n Source: `annual-reports/2023-24.pages.jsonl`\n- ence holder’s processes in relation to activity under each\nlicence and whether these processes meet legislative and licence requirements\nResult Met\nThe NHMRC Embryo Research Licensing Committee (ERLC) administers the Research\nInvolving Human Embryos Act 2002 (RIHE Act) and the Prohibition of Human Cloning\nfor Reproduction Act 2002 (PHCR Act). These Acts regulate the use of excess human\nembryos in research, including mitochondrial donation research, and prohibit certain\npractices, such as human cloning for reproduction.\nThe main functions of ERLC are to consider licence applications for\n Source: `annual-reports/2023-24.pages.jsonl`\n- ain national standards, codes and guidelines that promote best practice\nin research governance and ethics review processes and provide guidance on\nethical issues in health.\nEmbryo research regulation\n• Administer the Research Involving Human Embryos Act 2002 (RIHE Act) and the\nProhibition of Human Cloning for Reproduction Act 2002 (PCHR Act) through the\nwork of the Embryo Research Licensing Committee.\nNHMRC Annual Report 2024–25 73\n\n[page 74]\n3\nAnnual performance statements\nResearch is conducted responsibly, ethically and with integrity in Australia\nTarget 10: Research integrity matter\n Source: `annual-reports/2024-25.pages.jsonl`\n- nce holder’s processes in relation to activity\nunder each licence and whether these processes meet legislative\nand licence requirements.\nResult Met\nThe NHMRC Embryo Research Licensing Committee (ERLC) administers the Research\nInvolving Human Embryos Act 2002 (RIHE Act) and the Prohibition of Human Cloning\nfor Reproduction Act 2002 (PHCR Act). These Acts regulate the use of excess human\nembryos in research, and mitochondrial donation research, as well as prohibiting certain\npractices, such as human cloning for reproduction.\nThere were no instances of noncompliance in 2024–25, with licen\n Source: `annual-reports/2024-25.pages.jsonl`\n\n### Freedom of Information Act 1982\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 8\n**Register search**: https://www.legislation.gov.au/search?query=Freedom+of+Information+Act+1982\n\n**Sources**:\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- 70(2) of the Public Service Act 1999.\nThe report includes the matters set out in section 83 of the NHMRC Act, and also details\ninformation required by other applicable legislation, including the Public Governance,\nPerformance and Accountability Act 2013, the Freedom of Information Act 1982, the\nOccupational Health and Safety (Commonwealth Employment) Act 1991 and the Work\nHealth and Safety Act 2011.\nI certify that NHMRC has prepared fraud risk assessments and fraud control plans\nand has in place appropriate fraud prevention, detection, investig\n Source: `annual-reports/2014-15.pages.jsonl`\n- acy Act in 2014–15.\n86\nAnnual Report of the National Health and Medical Research Council 2014–2015 Annual Report of the National Health and Medical Research Council 2014–2015\n\n[page 95]\nCORPORATE REPORTING PART 3\nFREEDOM OF INFORMATION\nAgencies subject to the Freedom of Information Act 1982 (FOI Act) are required to publish information to the\npublic as part of the Information Publication Scheme (IPS). This requirement is in Part II of the FOI Act and\nhas replaced the former requirement to publish a section 8 statement in agency annual reports. T\n Source: `annual-reports/2014-15.pages.jsonl`\n- ffice of the Australian Information Commissioner (OIAC) under\nsection 30 of the Privacy Act 1988 in 2015–16. No determinations were served on NHMRC by the OAIC\nunder section 52 of the Privacy Act 1988 in 2015–16.\nFREEDOM OF INFORMATION\nAgencies subject to the Freedom of Information Act 1982 (FOI Act) are required to publish information to the\npublic as part of the Information Publication Scheme (IPS). This requirement is in Part II of the FOI Act and\nhas replaced the former requirement to publish a section 8 statement in agency annual reports. T\n Source: `annual-reports/2015-16.pages.jsonl`\n- OIAC) under\nsection 30 of the Privacy Act 1988 in 2016–17. No determinations were served on NHMRC by the OAIC\nunder section 52 of the Privacy Act 1988 in 2016–17.\nNHMRC’s privacy policy is currently under review.\nFreedom of information\nAgencies subject to the Freedom of Information Act 1982 (FOI Act) are required to publish information to the\npublic as part of the Information Publication Scheme (IPS). This requirement is in Part II of the FOI Act and\nhas replaced the former requirement to publish a section 8 statement in agency annual reports. T\n Source: `annual-reports/2016-17.pages.jsonl`\n- der section 30 of the Privacy\nAct. Similarly, no determinations were served on NHMRC by the OAIC under section 52 of\nthe Privacy Act.\nNHMRC had no eligible data breaches under the Notifiable Data Breaches scheme.\nFreedom of information\nAgencies subject to the Freedom of Information Act 1982 (FOI Act) are required to\npublish information as part of the Information Publication Scheme.\nOur Information Publication Scheme Plan details the type of information we publish and\nis available on the NHMRC website at www.nhmrc.gov.au/about-us/accountability-a\n Source: `annual-reports/2023-24.pages.jsonl`\n\n### Work Health and Safety Act 2011\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 7\n**Register search**: https://www.legislation.gov.au/search?query=Work+Health+and+Safety+Act+2011\n\n**Sources**:\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- and also details\ninformation required by other applicable legislation, including the Public Governance,\nPerformance and Accountability Act 2013, the Freedom of Information Act 1982, the\nOccupational Health and Safety (Commonwealth Employment) Act 1991 and the Work\nHealth and Safety Act 2011.\nI certify that NHMRC has prepared fraud risk assessments and fraud control plans\nand has in place appropriate fraud prevention, detection, investigation, reporting and\ndata collection procedures and processes to meet its specific needs and comply with\nthe Co\n Source: `annual-reports/2014-15.pages.jsonl`\n- C have\na good awareness of their responsibilities with regard to health and safety and to their own health and\nwellbeing.\nThere was one workers’ compensation claim lodged and accepted in 2014–15.\nDuring 2013–14, no incidents were reported to Comcare under the Work Health and Safety Act 2011 (WHS\nAct). There were no notices given to NHMRC under Part 10 of the WHS Act and there were no investigations\nconducted under the WHS Act.\nDISABILITY REPORTING\nSince 1994, Commonwealth departments and agencies have reported on their performance as policy\nadvi\n Source: `annual-reports/2014-15.pages.jsonl`\n- thin\nthe pay point increments of the enterprise agreement.\n\n[page 121]\nAnnual Report of the National Health and Medical Research Council 2016–2017 111\ntnemeganam\neLpoep\n4\nTRAP\nWork health and\nsafety\nNHMRC recognises the importance of its obligations under the Work Health and Safety Act 2011 (WHS\nAct) to prevent work-related injury and illness. NHMRC’s commitment to workplace health and safety is\narticulated through related policy and supporting documents and embodied in our actions and initiatives.\nHuman Resources has been working closely with m\n Source: `annual-reports/2016-17.pages.jsonl`\n- ons, flexible working\narrangements and financial reimbursements for eyesight testing.\nAnnual Report 2023-24 National Health and Medical Research Council 95\n\n[page 110]\nPart 5: People management\nWork health and safety incident reporting\nUnder section 38 of the Work Health and Safety Act 2011 (WHS Act), we are required to\nnotify Comcare of any deaths, dangerous incidents and serious injury or illness arising\nfrom our work. No notifiable incidents were reported to Comcare in 2023–24.\nUnder Schedule 2, Part 3 of the WHS Act, we are required to repor\n Source: `annual-reports/2023-24.pages.jsonl`\n- cal Research Council 185\n\n[page 200]\nAppendices\nW\nWarren, Robin, 26\nwebsite, 55, 65\nWesselingh, Steve, 6, 7, 34, 60, 93, 113\nWinship, Ingrid, xiv, 65\nwomen see gender equity in research\nWootten, Denise, 20, 31\nwork health and safety, 95\nincident reporting, 96\nWork Health and Safety Act 2011, 96\nworkers compensation premium, 96\nworkflow processes (grants), 54–5\nworking committees, 68–9\nworkplace agreements, 50, 90–2\nWorkplace Conversations (performance management framework), 88\nworkplace culture, 86–7\nworkplace diversity, iii, 87–8, 90\nWorld Heal\n Source: `annual-reports/2023-24.pages.jsonl`\n\n### PHCR Act) and the Research Involving Human Embryos Act 2002\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 5\n**Register search**: https://www.legislation.gov.au/search?query=PHCR+Act%29+and+the+Research+Involving+Human+Embryos+Act+2002\n\n**Sources**:\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- the National Health and Medical Research Council 2014–2015\n\n[page 80]\nPART 2 REPORT ON ACTIVITIES\nEMBRYO RESEARCH LICENSING COMMITTEE\nThe NHMRC Embryo Research Licensing Committee (ERLC) administers the Prohibition of Human Cloning\nfor Reproduction Act 2002 (PHCR Act) and the Research Involving Human Embryos Act 2002 (RIHE\nAct). These Acts regulate research activities that use human embryos created by assisted reproductive\ntechnology or other means. There are strong penalties for noncompliance. The Acts also prohibit human\ncloning for reproductive purposes.\nThe ERLC asses\n Source: `annual-reports/2014-15.pages.jsonl`\n- elease of the guidelines on 11 April 2016.\nA full list of AHEC members is available at Appendix 4.\nEmbryo Research Licensing Committee\nThe NHMRC Embryo Research Licensing Committee (ERLC) administers the Prohibition of Human Cloning\nfor Reproduction Act 2002 (PHCR Act) and the Research Involving Human Embryos Act 2002 (RIHE Act).\nThese acts regulate research activities that use human embryos created by assisted reproductive technology\nor other means. There are strong penalties for noncompliance. The Acts also prohibit human cloning for\nreproductive purposes.\n90\n\n[page 99]\n Source: `annual-reports/2015-16.pages.jsonl`\n- ctively, have membership of all the other\nPrincipal Committees.\nA list of AHEC members is in Appendix 3.\nEmbryo Research Licensing Committee\nThe Embryo Research Licensing Committee (ERLC) administers the Prohibition of Human Cloning for\nReproduction Act 2002 (PHCR Act) and the Research Involving Human Embryos Act 2002 (RIHE Act).\nThese Acts prohibit certain practices, including human cloning for reproduction. They also regulate use of\nexcess human embryos created through assisted reproductive technology, the creation of embryos by\nother means and use of such embryos for re\n Source: `annual-reports/2016-17.pages.jsonl`\n- territories on the above matters\n• make recommendations to the Minister for Health about expenditure on public health\nresearch and training, and medical research and training.\nNHMRC also administers the Prohibition of Human Cloning for Reproduction Act\n2002 (PHCR Act) and the Research Involving Human Embryos Act 2002 (RIHE Act).\nAdditionally, NHMRC exercises some statutory functions under the Medical Research\nFuture Fund Act 2015.\nGovernance\nNHMRC operates within a strong governance framework that supports effective\nperformance, integrity, efficiency and compliance with o\n Source: `annual-reports/2023-24.pages.jsonl`\n- s\non the above matters\n• make recommendations to the Minister for Health and Ageing about expenditure on\npublic health research and training, and medical research and training.\nNHMRC also administers the Prohibition of Human Cloning for Reproduction Act\n2002 (PHCR Act), and the Research Involving Human Embryos Act 2002 (RIHE Act).\nAdditionally, NHMRC exercises some statutory functions under the Medical Research\nFuture Fund Act 2015.\n90 NHMRC Annual Report 2024–25\n\n[page 91]\n4\nOperating environment\nGovernance and accountability\nNHMRC operates within a strong governance frame\n Source: `annual-reports/2024-25.pages.jsonl`\n\n### Sex Discrimination Act 1984\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 5\n**Register search**: https://www.legislation.gov.au/search?query=Sex+Discrimination+Act+1984\n\n**Sources**:\n- `pages/strategies-index.html`\n- `pages/strategies-index__04.html`\n- `annual-reports/2023-24.pages.jsonl`\n- `strategies/NHMRC_Gender_Equity_Strategy_FA.pages.jsonl`\n\n**Evidence contexts**:\n- research teams and research, including research participants.\nStrengthen guidance and training for peer reviewers to consider track record relative to opportunity, including career disruptions and circumstances.\nContinue to apply special measures\n2\nunder the\nSex Discrimination Act 1984\nto facilitate gender equity in the grant program, until the data demonstrates they are no longer required.\nKPI: Improved gender equity in the research and researchers NHMRC funds.\nPriority 2: Evidence and transparency about gender equity\nGoal: NHMRC actions a\n Source: `pages/strategies-index.html`\n- research teams and research, including research participants.\nStrengthen guidance and training for peer reviewers to consider track record relative to opportunity, including career disruptions and circumstances.\nContinue to apply special measures\n2\nunder the\nSex Discrimination Act 1984\nto facilitate gender equity in the grant program, until the data demonstrates they are no longer required.\nKPI: Improved gender equity in the research and researchers NHMRC funds.\nPriority 2: Evidence and transparency about gender equity\nGoal: NHMRC actions a\n Source: `pages/strategies-index__04.html`\n- nder equity and efforts to support a gender-inclusive\nhealth and medical research workforce. Across all schemes in our 2023 grant program,\nthe funded rate was higher for women than men. For the first time since the introduction\nof 2 special measures under the Sex Discrimination Act 1984 – to award equal numbers\nof Investigator Grants to women and men in the Leadership category and to include\nnon-binary researchers with women – women were awarded more funding than men.\nThis is a fantastic outcome and our initiatives will continue, although we\n Source: `annual-reports/2023-24.pages.jsonl`\n- ip Level 1. For the 2023 Ideas Grant round, the gap in funded rates\nbetween men and women of 1.5 percentage points was removed following the application\nof structural priority funding (Table 10).\n2023 was the first year that the new special measures under the Sex Discrimination Act\n1984 were introduced in the Investigator Grant scheme to address systemic disadvantage\nfaced by women and non-binary applicants. These measures extend targets to award\nan equal number of grants to women and men across the senior Leadership levels of\nthe scheme and\n Source: `annual-reports/2023-24.pages.jsonl`\n- and researchers\nprogram and medical research. 9 Strengthen guidance and training for peer reviewers to consider track record relative NHMRC funds.\nto opportunity, including career disruptions and circumstances.\n9 Continue to apply special measures2 under the Sex Discrimination Act 1984 to facilitate\ngender equity in the grant program, until the data demonstrates they are no longer required.\n2. E vidence and NHMRC actions and 9 Maintain or strengthen transparency in reporting on NHMRC grant applications and Transparent data are\ntransparency\n Source: `strategies/NHMRC_Gender_Equity_Strategy_FA.pages.jsonl`\n\n### Commonwealth Electoral Act 1918\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 4\n**Register search**: https://www.legislation.gov.au/search?query=Commonwealth+Electoral+Act+1918\n\n**Sources**:\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- nancy rating.\n98\nAnnual Report of the National Health and Medical Research Council 2014–2015 Annual Report of the National Health and Medical Research Council 2014–2015\n\n[page 107]\nCORPORATE REPORTING PART 3\nADVERTISING AND MARKET RESEARCH\nSection 311A of the Commonwealth Electoral Act 1918 requires NHMRC to disclose in its annual report the\namount paid by or on behalf of NHMRC during the financial year to the following:\n• advertising agencies (meaning creative advertising agencies that have developed advertising campaigns)\n• polling organisatio\n Source: `annual-reports/2014-15.pages.jsonl`\n- ster that records\nall assets held. The annual stocktake keeps records up to date, and each year assets\nare assessed for impairment. Our assets comprise office fit-out, furniture, equipment\nand systems.\nAdvertising and market research\nUnder section 311A of the Commonwealth Electoral Act 1918, NHMRC is required to\ndisclose payments of $13,000 or more (inclusive of GST) for advertising and market\nresearch. There was no reportable expenditure, and no advertising campaigns were\nconducted, in 2023–24.\nComplaints\nNHMRC has a complaints process for peop\n Source: `annual-reports/2023-24.pages.jsonl`\n- ment Policy: if there is an Indigenous business\nthat can deliver any new domestic contract between $80,000 and $200,000 on a\nvalue-for-money basis, NHMRC must offer the contract to that business first.\nAdvertising and market research\nUnder section 311A of the Commonwealth Electoral Act 1918, NHMRC is required to disclose\npayments of $13,000 or more (inclusive of GST) for advertising and market research. There\nwas no reportable expenditure and no advertising campaigns were conducted in 2024–25.\n120 NHMRC Annual Report 2024–25\n\n[page 121]\n4\nOperat\n Source: `annual-reports/2024-25.pages.jsonl`\n- 90, 92, 93, 94, 98–101\nworking committees, 17, 93, 102–6\ncommon-law contracts, 132, 168\nCommonwealth Child Safe Framework (CCSF), 115\nCommonwealth Climate Disclosure, 123\n192 NHMRC Annual Report 2024–25\n\n[page 193]\n8\nIndex\nCommonwealth Contracting Suite, 120\nCommonwealth Electoral Act 1918, 120\nCommonwealth Financial Framework, 118\nCommonwealth Fraud and Corruption Control Framework 2024, 112\nCommonwealth Ombudsman, 107\nCommonwealth Procurement Rules, 118\nCommonwealth States and Territories Joint (CSTJ) TCR Working Committee, 62\nCommunity Resea\n Source: `annual-reports/2024-25.pages.jsonl`\n\n### National Anti-Corruption Commission Act 2022\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 4\n**Register search**: https://www.legislation.gov.au/search?query=National+Anti-Corruption+Commission+Act+2022\n\n**Sources**:\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- ork\n2023–2025 and associated fraud and corruption control plan were developed in\naccordance with the Commonwealth Fraud Control Framework 2017, under the PGPA\nAct, the Australian Standard AS 8001:2021 (Fraud and corruption control) and the\nrequirements of the National Anti-Corruption Commission Act 2022.\nIn accordance with section 10 of the PGPA Act, NHMRC’s fraud and corruption control\nenvironment is built around taking all reasonable measures to prevent, detect and\nrespond to fraud and corruption. Our fraud and corruption controls include post-award\ncompli\n Source: `annual-reports/2023-24.pages.jsonl`\n- 3\nmitochondrial donation, 51, 53, 67\nMitochondrial Donation Law Reform (Maeve’s Law) Act 2022, 51\nMonash University, 15, 16, 20, 25\nMRFF Monitoring, evaluation and learning strategy 2020–21 to 2023–24, 63\nMurdoch Children’s Research Institute, xiii, 17, 102\nN\nNational Anti-Corruption Commission Act 2022, 75\nNational Australian Built Environment Rating System (NABERS), 84\nNational Blood Authority, 102\nNational green leasing policy, 73\nNational guideline for the assessment and diagnosis of autism in Australia 2023, 49, 62\nNational Health and Medical Research C\n Source: `annual-reports/2023-24.pages.jsonl`\n- ers. The NHMRC Fraud and Corruption Control\nFramework 2024–2026 and associated fraud and corruption control plan were developed\nin accordance with the Commonwealth Fraud and Corruption Control Framework\n2024 under the PGPA Act and with the requirements of the National Anti-Corruption\nCommission Act 2022.\nIn accordance with section 10 of the PGPA Act, NHMRC’s fraud and corruption control\nenvironment is built around taking all reasonable measures to prevent, detect and respond\nto fraud and corruption. Fraud and corruption controls may include mechanisms such\na\n Source: `annual-reports/2024-25.pages.jsonl`\n- terial advisory committees, 107\nmission (of NHMRC), 16, 57\nmitochondrial donation research, 8, 75, 101\nMonash University, 33, 34, 36, 40, 84\nmultiple long-term conditions, 17, 19\nMurdoch Children’s Research Institute, 84\nMurray, Richard, 96\nN\nNAIDOC Week, 128\nNational Anti-Corruption Commission Act 2022, 112\nNational Australian Built Environment Rating System (NABERS) energy rating, 124\nNational Bowel Cancer Screening Program (NBCSP), 85\nNational guideline for newborn screening in spinal muscular atrophy in Australia\nand Aotearoa New Zealand, 9, 71, 97\nNatio\n Source: `annual-reports/2024-25.pages.jsonl`\n\n### PGPA Act Public Governance, Performance and Accountability Act 2013\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 4\n**Register search**: https://www.legislation.gov.au/search?query=PGPA+Act+Public+Governance%2C+Performance+and+Accountability+Act+2013\n\n**Sources**:\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- ementia Research\nNSFC National Natural Science Foundation of China\nOIAC Office of the Australian Information Commissioner\nOTA Organ and Tissue Authority\nPCIC Principal Committee Indigenous Caucus\nPHCR Act Prohibition of Human Cloning for Reproduction Act 2002\nPGPA Act Public Governance, Performance and Accountability Act 2013\nPGPA Rule Public Governance, Performance and Accountability Rule 2014\nPIR post implementation review\nRC Research Committee\nRF Research Fellowship\nRGMS Research Grants Management System\nRIHE Act Research Involving Human Embryos Act 2002\nRMF Risk Management Pol\n Source: `annual-reports/2015-16.pages.jsonl`\n- Priority Area\nNNIDR NHMRC National Institute for Dementia Research\nOIAC Office of the Australian Information Commissioner\nOTA Organ and Tissue Authority\nPCIC Principal Committee Indigenous Caucus\nPHCR Act Prohibition of Human Cloning for Reproduction Act 2002\nPGPA Act Public Governance, Performance and Accountability Act 2013\nPGPA Rule Public Governance, Performance and Accountability Rule 2014\nPIR post implementation review\nRC Research Committee\nRF Research Fellowship\nRIHE Act Research Involving Human Embryos Act 2002\nRMF Risk Management Policy and Framework\nRMS Rehabilitation Ma\n Source: `annual-reports/2016-17.pages.jsonl`\n- on Commissioner\nOAM Medal of the Order of Australia\nOCHRe Our Collaborations in Health Research\nPBB protracted bacterial bronchitis\nPBS Portfolio Budget Statements\nPCIC Principal Committee Indigenous Caucus\nPFAS per-fluoroalkyl and poly-fluoroalkyl substances\nPGPA Act Public Governance, Performance and Accountability Act 2013\nPGPA Rule Public Governance, Performance and Accountability Rule 2014\nPGS postgraduate scholarship\nPHCR Act Prohibition of Human Cloning for Reproduction Act 2002\nPhD Doctor of Philosophy\nPP Partnership Project\nPSM Public Service Medal\nQIMR Queensland Institu\n Source: `annual-reports/2023-24.pages.jsonl`\n- ncil\nNSW New South Wales\nNT Northern Territory\nO\nOAIC Office of the Australian Information Commissioner\nOAM Medal of the Order of Australia\nOSM optimal management structure\nP\nPBS Portfolio Budget Statements\nPFAS per-fluoroalkyl and poly-fluoroalkyl substances\nPGPA Act Public Governance, Performance and Accountability Act 2013\nPGPA Rule Public Governance, Performance and Accountability Rule 2014\nPHCR Act Prohibition of Human Cloning for Reproduction Act 2002\nPHHSC Public Health and Health Systems Committee\nPhD Doctor of Philosophy\nPRM peer review mentor\nPSM Public Service Medal\nQ\nQ\n Source: `annual-reports/2024-25.pages.jsonl`\n\n### Auditor-General Act 1997\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 3\n**Register search**: https://www.legislation.gov.au/search?query=Auditor-General+Act+1997\n\n**Sources**:\n- `annual-reports/2016-17.pages.jsonl`\n- `annual-reports/2023-24.pages.jsonl`\n- `annual-reports/2024-25.pages.jsonl`\n\n**Evidence contexts**:\n- the Auditor-General and his delegates. These include the relevant\nindependence requirements of the Accounting Professional and Ethical Standards Board’s APES 110 Code of\nEthics for Professional Accountants to the extent that they are not in conflict with the Auditor-General Act 1997\n(the Code). I have also fulfilled my other responsibilities in accordance with the Code. I believe that the audit\nevidence I have obtained is sufficient and appropriate to provide a basis for my opinion.\nAccountable Authority’s Responsibility for the Financia\n Source: `annual-reports/2016-17.pages.jsonl`\n- include the relevant independence requirements of the\nAccounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants\n(including Independence Standards) (the Code) to the extent that they are not in conflict with the\nAuditor-General Act 1997. I have also fulfilled my other responsibilities in accordance with the Code. I believe\nthat the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.\nAccountable Authority’s responsibility for the financial statement\n Source: `annual-reports/2023-24.pages.jsonl`\n- include the relevant independence requirements of the\nAccounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants\n(including Independence Standards) (the Code) to the extent that they are not in conflict with the Auditor-\nGeneral Act 1997. I have also fulfilled my other responsibilities in accordance with the Code. I believe that the\naudit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.\nAccountable Authority’s responsibility for the financial statement\n Source: `annual-reports/2024-25.pages.jsonl`\n\n### Data Availability and Transparency Act 2022\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 3\n**Register search**: https://www.legislation.gov.au/search?query=Data+Availability+and+Transparency+Act+2022\n\n**Sources**:\n- `annual-reports/2023-24.pages.jsonl`\n\n**Evidence contexts**:\n- reliable, accessible and reusable by NHMRC,\nthe Australian Government and other relevant data consumers.\nSource NHMRC Corporate Plan 2023–24\nQualitative methods to demonstrate that data under NHMRC’s custodianship is\nMethodology\nmanaged in accordance with the Data Availability and Transparency Act 2022\nResult Partially met\nThe Data Availability and Transparency Act 2022 (the DAT Act) outlines the approach to\nauthorise and regulate access to Australian Government data. The DAT Act authorises\npublic sector data custodians to share data with accredited users i\n Source: `annual-reports/2023-24.pages.jsonl`\n- ment and other relevant data consumers.\nSource NHMRC Corporate Plan 2023–24\nQualitative methods to demonstrate that data under NHMRC’s custodianship is\nMethodology\nmanaged in accordance with the Data Availability and Transparency Act 2022\nResult Partially met\nThe Data Availability and Transparency Act 2022 (the DAT Act) outlines the approach to\nauthorise and regulate access to Australian Government data. The DAT Act authorises\npublic sector data custodians to share data with accredited users in accordance with\nspecific authorisations, purposes, principles and a\n Source: `annual-reports/2023-24.pages.jsonl`\n- il of NHMRC, xiv, 58, 59–63\nChair, xiv, 60\nfunctions, xiii, 59\nmeetings, 61–2\nmembers and membership, xiv, 59–60\nPrincipal Committees, xiii, xiv, 58, 60, 63–7\nworking committees, 68–9\nCreating Liveable Cities in Australia study, 98\ncustodianship of data, 55\nD\nData Availability and Transparency Act 2022, 55\ndata custodianship, 55\nDavid Cooper Clinical Trials and Cohort Studies Award, 15\ndementia, iv, 5, 11\nDepartment of Finance, 82, 106\nDepartment of Health and Aged Care, 11, 37, 106\nDevelopment Grants, iii, 9, 10, 30\ndiabetes, iv, 5\nDigital Technology Agenc\n Source: `annual-reports/2023-24.pages.jsonl`\n\n### Environmental Protection and Biodiversity Conservation Act 1999\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 3\n**Register search**: https://www.legislation.gov.au/search?query=Environmental+Protection+and+Biodiversity+Conservation+Act+1999\n\n**Sources**:\n- `annual-reports/2014-15.pages.jsonl`\n- `annual-reports/2015-16.pages.jsonl`\n- `annual-reports/2\n\n_…truncated, open the .md file for the full content._", "global_initiatives_md": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": null, "vision_source_page": null, "purposes": "NHMRC’s purposes support our mission of building a healthy Australia and collectively capture NHMRC’s legislated functions. [CP p.10]", "purposes_source_page": 10, "how_we_deliver": "NHMRC’s strategy for health and medical research helps to focus our activity to ensure we achieve our mission of building a healthy Australia and contributes to the broader research and innovation system in Australia. [CP p.13]", "how_we_deliver_source_page": 13, "government_priorities": [ { "text": "Aboriginal and Torres Strait Islander health", "source_page": 18 }, { "text": "Artificial intelligence in health", "source_page": 18 }, { "text": "Emerging health threats and emergencies", "source_page": 18 }, { "text": "Multiple long-term conditions", "source_page": 18 } ], "outcomes": [ { "name": "Outcome 1: Improved health and medical knowledge", "description": "Create knowledge and build research capability through investment in the highest-quality health and medical research, and the best researchers. [AR p.15]", "key_activities": [ "fund health and medical research and training", "issue guidelines on and advise the community on matters related to health and medical research", "advise the community on ethical issues relating to health" ], "source_page": 15 }, { "name": "Outcome 2: Translation of health and medical research", "description": "Drive the translation of health and medical research into public policy, health systems and clinical practice and support the commercialisation of research discoveries. [AR p.15]", "key_activities": [ "fund health and medical research and training", "issue guidelines on and advise the community on matters related to health and medical research", "advise the community on ethical issues relating to health" ], "source_page": 15 }, { "name": "Outcome 3: Integrity of research", "description": "Maintain a strong integrity framework underpinning rigorous and ethical research, and promoting community trust. [AR p.15]", "key_activities": [ "fund health and medical research and training", "issue guidelines on and advise the community on matters related to health and medical research", "advise the community on ethical issues relating to health" ], "source_page": 15 } ], "values": [ "Investment", "Translation", "Integrity" ], "values_framework_name": "NHMRC’s mission and purposes", "kpi_targets_2025_26": [ { "code": "CCE01", "measure": "Grants are awarded, based on expert peer review, distribution of the value of new grants across the full spectrum of health and medical research, and include national, state and territory and community priorities", "target": "Target/s Methodology Measure type Reporting years", "source_page": 47 }, { "code": "CCE02", "measure": "More than 5% of NHMRC’s annual budget is awarded to research that aims to improve health outcomes for Aboriginal and Torres Strait Islander people", "target": "Quantitative assessment of the number of grants, amount of funding awarded and funded rates by gender, and whether measures have been applied to reduce gender disparities", "source_page": 47 }, { "code": "CCE03", "measure": "Research is conducted responsibly, ethically and with integrity in Australia", "target": "Compliance with regulatory requirements under the Research Involving Human Embryos Act 2002", "source_page": 49 }, { "code": "CCE04", "measure": "Research involving human embryos is conducted ethically and legally in accordance with appropriate licence conditions", "target": "Qualitative assessment from inspections and six-monthly reports", "source_page": 49 } ], "kpi_results_2024_25": [ { "code": "CCE01", "measure": "Grants are awarded, based on expert peer review, distribution of the value of new grants across the full spectrum of health and medical research, and include national, state and territory and community priorities", "result": "8.9% of new grants awarded (by value) to research on health in Aboriginal and Torres Strait Islander people", "status": "Achieved", "source_page": 19 }, { "code": "CCE02", "measure": "More than 5% of NHMRC’s annual budget is awarded to research that aims to improve health outcomes for Aboriginal and Torres Strait Islander people", "result": "4.4% of new grants were led by chief investigators of Aboriginal and/or Torres Strait Islander descent", "status": "Achieved", "source_page": 19 }, { "code": "CCE03", "measure": "Research is conducted responsibly, ethically and with integrity in Australia", "result": "Target met", "status": "Achieved", "source_page": 19 }, { "code": "CCE04", "measure": "Research involving human embryos is conducted ethically and legally in accordance with appropriate licence conditions", "result": "Target met", "status": "Achieved", "source_page": 19 } ], "_source_urls": { "annual_report_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf", "corporate_plan_url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf" } }, "ideas": [ { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "Table 4: Criteria used to determine NHMRC performance\nCriteria for result by target type\nResult Quantified target Qualitative or mixed targeta\nMeasured result reaches or Assessment demonstrates achievement\nMet\nexceeds the quantified target of the target as described\nAssessment demonstrates some\nPartially met N/A achievement and some non-achievement\nof the target as described\nAssessment demonstrates significant\nMeasured result is less than\nNot met non-achievement of the target as described,\nthe quantified target\nsuch as failure to achieve a critical part\nN/A, not applicable\na Includes targets where achievement is measured by qualitative assessment of quantifiable information,\nsuch as distribution of funding (Target 1) and compliance reporting (Target 10)\n58 NHMRC Annual Report 2024–25", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "Table 4: Criteria used to determine NHMRC performance\nCriteria for result by target type\nResult Quantified target Qualitative or mixed targeta\nMeasured result reaches or Assessment demonstrates achievement\nMet\nexceeds the quantified target of the target as described\nAssessment demonstrates some\nPartially met N/A achievement and some non-achievement\nof the target as described\nAssessment demonstrates significant\nMeasured result is less than\nNot met non-achievement of the target as described,\nthe quantified target\nsuch as failure to achieve a critical part\nN/A, not applicable\na Includes targets where achievement is measured by qualitative assessment of quantifiable information,\nsuch as distribution of funding (Target 1) and compliance reporting (Target 10)\n58 NHMRC Annual Report 2024–25", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "[Page 189]\n8\nIndex\nantimicrobial resistance, 9, 18, 63\napproved guidelines, 71\nAPS Employee Census, 130–1, 134\nAPS Executive Remuneration Management Policy, 132\nAPS Net Zero 2030, 122\nAPS Strategic Commissioning Framework, 127\nAPS values, 112, 126\narthritis research, 2, 19\nartificial intelligence in health, 17, 18, 100\nArya, Dinesh, 95\nAsselin-Labat, Marie-Liesse, 38\nasthma research, 2, 19\nattention deficit hyperactive disorders (ADHD), 109\nAudit and Risk Committee, 91, 109–11, 112\ninternal audit arrangements, 111\nmembers and meeting attendance, 109–10\nAuditor-General\nperformance audits, 108\nsee also Australian National Audit Office\naudits\nfinancial statements, 141–2\ninternal audit, 111\nperformance audits, 108\nAusTender, 118\nAustralia and New Zealand Dialysis and Transplant Registry (ANZDATA), 82\nAustralian and New Zealand Clinical Guidelines for Stroke Management, 10, 71, 79, 96, 97", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "[Page 189]\n8\nIndex\nantimicrobial resistance, 9, 18, 63\napproved guidelines, 71\nAPS Employee Census, 130–1, 134\nAPS Executive Remuneration Management Policy, 132\nAPS Net Zero 2030, 122\nAPS Strategic Commissioning Framework, 127\nAPS values, 112, 126\narthritis research, 2, 19\nartificial intelligence in health, 17, 18, 100\nArya, Dinesh, 95\nAsselin-Labat, Marie-Liesse, 38\nasthma research, 2, 19\nattention deficit hyperactive disorders (ADHD), 109\nAudit and Risk Committee, 91, 109–11, 112\ninternal audit arrangements, 111\nmembers and meeting attendance, 109–10\nAuditor-General\nperformance audits, 108\nsee also Australian National Audit Office\naudits\nfinancial statements, 141–2\ninternal audit, 111\nperformance audits, 108\nAusTender, 118\nAustralia and New Zealand Dialysis and Transplant Registry (ANZDATA), 82\nAustralian and New Zealand Clinical Guidelines for Stroke Management, 10, 71, 79, 96, 97", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Staff Productivity", "scale": "small", "title": "Reusable briefing and summary assistant for internal documents", "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.", "quote": "Table 2 Portfolio Budget Statement – NHMRC expenses and resources\nOutcome 1: Improved health and medical knowledge,\nincluding through funding research, translating Actual\nresearch findings into evidence-based clinical Budget* Expenses Variation\npractice, administering legislation governing research, 2014-15 2014-15 2014-15\nissuing guidelines and advice for ethics in health and $’000 $’000 $’000\nthe promotion of public health. (a) (b) (a)-(b)\nProgramme 1.1: Health and Medical Research\nAdministered expenses\nOrdinary Annual Services (Appropriation Act No.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Staff Productivity", "scale": "large", "title": "Department-wide knowledge and briefing platform", "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.", "quote": "Table 2 Portfolio Budget Statement – NHMRC expenses and resources\nOutcome 1: Improved health and medical knowledge,\nincluding through funding research, translating Actual\nresearch findings into evidence-based clinical Budget* Expenses Variation\npractice, administering legislation governing research, 2014-15 2014-15 2014-15\nissuing guidelines and advice for ethics in health and $’000 $’000 $’000\nthe promotion of public health. (a) (b) (a)-(b)\nProgramme 1.1: Health and Medical Research\nAdministered expenses\nOrdinary Annual Services (Appropriation Act No.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "annual-reports/2014-15.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Regulation & Policy", "scale": "small", "title": "Regulatory burden scan for forms, guidance, and reporting", "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.", "quote": "Target Methodology Measure type Reporting years\n12 Compliance with Qualitative assessment from Effectiveness 2025–26\nregulatory requirements inspections and six-monthly reports 2026–27\nunder the Research is used to calculate the number and\n2027–28\nInvolving Human type of incidents of non-compliance\nEmbryos Act 2002. with licence conditions by each licence 2028–29\nholder in the period, as well as how\nquickly and effectively any actions to\nredress non-compliance (as required\nby the regulator) are actioned by the\nlicence holder.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Regulated entities / policy teams", "source": "corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Regulation & Policy", "scale": "large", "title": "Adaptive regulation program with live feedback loops", "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.", "quote": "Target Methodology Measure type Reporting years\n12 Compliance with Qualitative assessment from Effectiveness 2025–26\nregulatory requirements inspections and six-monthly reports 2026–27\nunder the Research is used to calculate the number and\n2027–28\nInvolving Human type of incidents of non-compliance\nEmbryos Act 2002. with licence conditions by each licence 2028–29\nholder in the period, as well as how\nquickly and effectively any actions to\nredress non-compliance (as required\nby the regulator) are actioned by the\nlicence holder.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Regulated entities / policy teams", "source": "corporate-plans/2025-26.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Case Processing", "scale": "small", "title": "Triage queue for stuck or ageing cases", "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.", "quote": "Table 4: Criteria used to determine NHMRC performance\nCriteria for result by target type\nResult Quantified target Qualitative or mixed targeta\nMeasured result reaches or Assessment demonstrates achievement\nMet\nexceeds the quantified target of the target as described\nAssessment demonstrates some\nPartially met N/A achievement and some non-achievement\nof the target as described\nAssessment demonstrates significant\nMeasured result is less than\nNot met non-achievement of the target as described,\nthe quantified target\nsuch as failure to achieve a critical part\nN/A, not applicable\na Includes targets where achievement is measured by qualitative assessment of quantifiable information,\nsuch as distribution of funding (Target 1) and compliance reporting (Target 10)\n58 NHMRC Annual Report 2024–25", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Case Processing", "scale": "large", "title": "End-to-end case processing redesign", "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.", "quote": "Table 4: Criteria used to determine NHMRC performance\nCriteria for result by target type\nResult Quantified target Qualitative or mixed targeta\nMeasured result reaches or Assessment demonstrates achievement\nMet\nexceeds the quantified target of the target as described\nAssessment demonstrates some\nPartially met N/A achievement and some non-achievement\nof the target as described\nAssessment demonstrates significant\nMeasured result is less than\nNot met non-achievement of the target as described,\nthe quantified target\nsuch as failure to achieve a critical part\nN/A, not applicable\na Includes targets where achievement is measured by qualitative assessment of quantifiable information,\nsuch as distribution of funding (Target 1) and compliance reporting (Target 10)\n58 NHMRC Annual Report 2024–25", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "annual-reports/2024-25.pdf (https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Procurement & Delivery", "scale": "small", "title": "Procurement lessons library for repeat purchases", "idea": "Capture reusable procurement clauses, market lessons, supplier performance notes, and common evaluation criteria.", "quote": "[Page 16]\nTable 1 Investigator Initiated and Priority Driven NHMRC Funding\nOutcomes in 20157\nMAIN 2015\nFUNDING GRANT TYPE[a] GRANT SUB-TYPE\nINVESTIGATOR PRIORITY\nGROUP\nNew Investigator Grant $14,996,978\nStandard Project Grant $383,431,356\nProject Grants\nAboriginal and Torres Strait Islander\n$21,246,639\nHealth Research\nProgram Grants Program Grant $108,742,325\nCentre of Research Excellence\n$12,149,997\n– Clinical\nCentres of Research Centre of Research Excellence\n$12,198,638\nExcellence – Health Services\nCentre of Research Excellence\n$12,478,085\n– Population Health\nDevelopment Grants Development Grant $14,142,312\nPartnership Projects Partnership Project for Better Health $18,436,290\nAust/EU Collaborative Research\n$5,495,919\nGrant\nCalifornia Institute for Regenerative\nResearch Medicine (CIRM) – Tools and $1,784,170\nSupport Technologies Stem Cells Research\nInternational", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Delivery teams / suppliers", "source": "corporate-plans/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "category": "Procurement & Delivery", "scale": "large", "title": "Portfolio delivery office for major investments", "idea": "Stand up a portfolio delivery office that tracks benefits, risks, dependencies, procurement, and delivery confidence.", "quote": "[Page 16]\nTable 1 Investigator Initiated and Priority Driven NHMRC Funding\nOutcomes in 20157\nMAIN 2015\nFUNDING GRANT TYPE[a] GRANT SUB-TYPE\nINVESTIGATOR PRIORITY\nGROUP\nNew Investigator Grant $14,996,978\nStandard Project Grant $383,431,356\nProject Grants\nAboriginal and Torres Strait Islander\n$21,246,639\nHealth Research\nProgram Grants Program Grant $108,742,325\nCentre of Research Excellence\n$12,149,997\n– Clinical\nCentres of Research Centre of Research Excellence\n$12,198,638\nExcellence – Health Services\nCentre of Research Excellence\n$12,478,085\n– Population Health\nDevelopment Grants Development Grant $14,142,312\nPartnership Projects Partnership Project for Better Health $18,436,290\nAust/EU Collaborative Research\n$5,495,919\nGrant\nCalifornia Institute for Regenerative\nResearch Medicine (CIRM) – Tools and $1,784,170\nSupport Technologies Stem Cells Research\nInternational", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Delivery teams / suppliers", "source": "corporate-plans/2016-17.pdf (https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] } ], "legislation_administered": [], "artifacts": [ { "category": "annual-reports", "year": "2024-25", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf", "file": "annual-reports/2024-25.pdf", "bytes": 3490598, "link_text": "Annual Report 2024–25" }, { "category": "annual-reports", "year": "2023-24", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/NHMRC-Annual-Report-2023-24-20012025.pdf", "file": "annual-reports/2023-24.pdf", "bytes": 11867070, "link_text": "Annual Report 2023–24" }, { "category": "annual-reports", "year": "2016-17", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/b1265726-e6c9-42a4-b2e1-cdef3ce84e68/upload_pdf/nhmrc_annualreport2016-2017.pdf;fileType=application%2Fpdf", "file": "annual-reports/2016-17.pdf", "bytes": 5640749, "link_text": "2016–17" }, { "category": "annual-reports", "year": "2015-16", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/ed0e0bfe-feb1-40bb-ba07-01cfa956533c/upload_pdf/16243_nhmrc_annual_report_2015-16_web_2.pdf;fileType=application%2Fpdf", "file": "annual-reports/2015-16.pdf", "bytes": 3717899, "link_text": "2015–16" }, { "category": "annual-reports", "year": "2014-15", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/a2dc2a8f-9967-4f76-b5b9-35c71c622ebd/upload_pdf/nh169_nhmrc_annual_report_2014_15_web.pdf", "file": "annual-reports/2014-15.pdf", "bytes": 3357215, "link_text": "2014–15" }, { "category": "corporate-plans", "year": "2025-26", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "file": "corporate-plans/2025-26.pdf", "bytes": 8185819, "link_text": "NHMRC Corporate Plan 2025–26" }, { "category": "corporate-plans", "year": "2024-25", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/Corporate-Plan-2024-25.pdf", "file": "corporate-plans/2024-25.pdf", "bytes": 3133387, "link_text": "NHMRC Corporate Plan 2024–25" }, { "category": "corporate-plans", "year": "2018-19", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/77446457-0aed-405b-b234-73321c169df2/upload_pdf/corporate-plan-2018-2019.pdf;fileType=application%2Fpdf", "file": "corporate-plans/2018-19.pdf", "bytes": 1590102, "link_text": "2018–19" }, { "category": "corporate-plans", "year": "2017-18", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/4ba2e828-a6a9-4c84-beab-a45c39967b6e/upload_pdf/17293_nhmrc_corporate_plan_2017-18-web.pdf;fileType=application%2Fpdf", "file": "corporate-plans/2017-18.pdf", "bytes": 1529952, "link_text": "2017–18" }, { "category": "corporate-plans", "year": "2016-17", "url": "https://parlinfo.aph.gov.au/parlInfo/download/publications/tabledpapers/2d6f9cb6-500b-4651-a2ad-d7785ebffe53/upload_pdf/16390_nhmrc_-_nhmrc_corporate_plan_2016-17_0.pdf;fileType=application%2Fpdf", "file": "corporate-plans/2016-17.pdf", "bytes": 1565711, "link_text": "2016–17" }, { "category": "strategies", "year": null, "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/NHMRC_Gender_Equity_Strategy_FA.pdf", "file": "strategies/NHMRC_Gender_Equity_Strategy_FA.pdf", "bytes": 112699, "link_text": "NHMRC Gender Equity Strategy" }, { "category": "strategies", "year": null, "url": "https://www.canceraustralia.gov.au/sites/default/files/migrated-files/publications/national_consumer_framework_web_504af020f2184.pdf", "file": "strategies/national_consumer_framework_web_504af020f2184.pdf", "bytes": 2621196, "link_text": "National Framework for Consumer Involvement in Cancer Control | Cancer Australia" }, { "category": "reviews", "year": null, "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/final-report-national-scientific-committees.pdf", "file": "reviews/final-report-national-scientific-committees.pdf", "bytes": 1962346, "link_text": "Report from the pilot – National Scientific Committee" }, { "category": "other-pdfs", "year": "2018", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-november-2018.pdf", "file": "other-pdfs/council-minutes-november-2018.pdf", "bytes": 665616, "link_text": "Report of the 215th Session of the NHMRC Council (21–22 November 2018)" }, { "category": "other-pdfs", "year": "2018", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-june-2018.pdf", "file": "other-pdfs/council-minutes-june-2018.pdf", "bytes": 248428, "link_text": "Report of the 214th Session of the NHMRC Council (27–28 June 2018)" }, { "category": "other-pdfs", "year": "2018", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-march-2018.pdf", "file": "other-pdfs/council-minutes-march-2018.pdf", "bytes": 224976, "link_text": "Report of the 213th Session of the NHMRC Council (20–21 March 2018)" }, { "category": "other-pdfs", "year": "2017", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-october-2017.pdf", "file": "other-pdfs/council-minutes-october-2017.pdf", "bytes": 219581, "link_text": "Report of the 212th Session of the NHMRC Council (11–12 October 2017)" }, { "category": "other-pdfs", "year": "2017", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/reports/Annual%20reports/council-minutes-july-2017.pdf", "file": "other-pdfs/council-minutes-july-2017.pdf", "bytes": 212991, "link_text": "Report of the 211th Session of the NHMRC Council (12–13 July 2017)" } ], "_meta": { "snapshot_built_at": "2026-05-13T11:02:56+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "annual_report": { "file": "annual-reports\\2024-25.txt", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/NHMRC_Annual_Report_2024-25_v10_wa.pdf", "year": "2024-25" }, "corporate_plan": { "file": "corporate-plans\\2025-26.txt", "url": "https://www.nhmrc.gov.au/sites/default/files/documents/attachments/publications/Corporate-Plan-2025-26.pdf", "year": "2025-26" }, "usage": { "input_tokens": 37527, "output_tokens": 1292, "total_tokens": 38819, "model": "nova-micro" }, "cost_usd": 0.0014943250000000001, "elapsed_seconds": 32.49, "generated_at": "2026-05-13T04:08:05+00:00" }, "ideas_manifest": { "entity_id": "B-001935", "entity_name": "National Health and Medical Research Council - Commissioner of Complaints", "folder_name": "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints", "generated_at": "2026-05-09T23:05:41.162469+00:00", "idea_count": 12, "markdown": "ideas/National-Health-and-Medical-Research-Council-Commissioner-of-Complaints_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "National-Health-and-Medical-Research-Council-Commissioner-of-Complaints_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }